

PCT/GB 98 / 01619
09 / 445289

The
Patent
Office

The Patent Office
Concept House
Cardiff Road
Newport
South Wales

NP9 1RH REC'D 29 JUN 1998

PRIORITY DOCUMENT

WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed




Dated

22 June 1998

BEST AVAILABLE COPY

This Page Blank (uspto)



Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

P57398P

2. Patent application number

(The Patent Office will fill in this part)

27 MAY 1998

9811221.2

3. Full name, address and postcode of the or of each applicant (underline all surnames)

The University of Wales,
Aberystwyth, Old College
King Street
Aberystwyth
SY23 2AX

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

7224553EC /

4. Title of the invention

BACTERIAL PHEROMONES AND USES THEREFOR

5. Name of your agent (if you have one)

Fry Heath & Spence

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

The Old College
53 High Street
Horley
Surrey RH6 7BN

Patents ADP number (if you know it)

05880273001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

YES

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 40

Claim(s) 7

Abstract

Drawing(s) 20 + 20

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature Fry Heath & Spence Date 26.05.98

12. Name and daytime telephone number of person to contact in the United Kingdom

Dr V.A. Price - Tel: 01293 776880

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.*
- Write your answers in capital letters using black ink or you may type them.*
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.*
- Once you have filled in the form you must remember to sign and date it.*
- For details of the fee and ways to pay please contact the Patent Office.*

BACTERIAL PHEROMONES AND USES THEREFOR

Field of the invention

The present invention relates to RP-factors, their cognate receptors, convertases, respective genes and to inhibitors or mimetics thereof. In particular, the invention relates to antibodies, pharmaceutical compositions and (therapeutic, diagnostic) methods based on the RP-factors and their receptors/convertases.

Introduction

Bacterial pheromones

It is known that certain chemicals may mediate intercellular communication in bacterial cultures. Such communication has been shown to be of importance during sporulation, conjugation, changes in virulence and in bioluminescence. It is now clear that a variety of different autocrine and/or paracrine chemical compounds ("pheromones") produced as secondary metabolites are responsible for such social behaviour in prokaryotes (see e.g. Kell et al, 1995, Trends Ecol. Evolution, 10, 126-129).

Pheromones may be distinguished from nutrients inter alia in that: (i) they are produced by the organisms themselves, (ii) they are active at very low concentrations (e.g. at picomolar or nanomolar concentrations), and (iii) with the exception of prohormone processing, their *metabolism* is not necessary for activity (although they may of course ultimately be degraded).

The chemical nature of these pheromonal compounds varies widely: those associated with Gram-negative organisms tend to be of low molecular weight (e.g. N-acyl homoserine lactone derivatives), whilst a number of Gram-positive organisms use proteins and polypeptides (Kell et al, 1995, *ibidem*).

Pheromones are also known to play an important role in the development of bacterial cultures. For unstressed (uninjured) bacteria and optimal growth media, the "self-promoting" mode of culture growth is normally masked due to the high rate of production of growth factors and the sensitivity of the cells to these pheromones. Only under unfavourable conditions (for example, poor growth media, small initial inocula and/or starved cells) is this self-promoting behaviour "visible".

For example, a dramatic reduction in the length of the lag phase of cultures of *Nitrosomonas europaea* is mediated by N-(3-oxo-hexanoyl) homoserine lactone, and chorionic gonadotropin-like ligand (a 48kD protein) had similar growth-stimulating activity for *Xanthomonas maltophilia*. A number of mammalian hormones (including peptide and steroid hormones as well as cytokines) have also been shown to exhibit

potent growth-stimulating activities for both Gram-positive and Gram-negative bacteria.

Latency and resuscitation

5 The ability of a microbial cell to grow and divide on a nutrient agar plate constitutes the benchmark method for determining the number of living cells in a sample of interest. However, it is also widely recognised that, especially in nature, the distinction between life and non-life is not absolute; many cells may exist in "dormant" or "moribund" forms or states and will not produce colonies on nutrient media (i.e. are "non-culturable").

10 However, these dormant or latent cells are not dead: they can be returned, by a process known as resuscitation, to a state of viability/ culturability.

For example, it is known that cells of the (high-G + C Gram-positive) bacterium *Micrococcus luteus* can enter a state of true dormancy from which they may be

15 resuscitated by culture supernatants, even in the absence of any 'initially viable' cells.

The latent state has profound medical implications: many pathogenic bacteria (including pathogenic mycobacteria such as *M. tuberculosis*) are known to persist for extended periods in latent states in a host organism. Indeed, tuberculosis is a re-emergent

20 infection of great concern, and it is recognised in particular that the causative organism (*Mycobacterium tuberculosis*) can lie dormant (remain latent) in patients and carriers for periods of years.

The latent state also has important commercial implications, since it complicates many

25 laboratory methods for the detection, cultivation and enumeration of bacteria (for example in the food and healthcare industries).

There is therefore a pressing need to understand the physiological bases of latency and resuscitation.

30

Summary of the invention

The present invention is based, at least in part, on the discovery of a new class of pheromones which stimulate the resuscitation of bacteria after true dormancy. This

35 "resuscitation factor" (herein embraced by the term "RP-factor") may exhibit activity at picomolar concentrations (implying a non-nutritional role). The elucidation of the structure of the pheromones at the amino acid sequence level has also permitted the present inventors to describe a larger family of proteins, some members of which act more broadly as regulators of cellular growth or replication and not necessarily as

40 resuscitation promoting factors. Further sequence comparisons have also led to the identification of the cognate receptors, at least some of which share certain sequence similarities with their cognate RP-factors.

Thus, in a first aspect of the present invention there is provided an isolated RP-factor.

45

RP-factors

The term "RP-factor" is used herein to encompass any representative of that family of substances the members of which are capable of resuscitating dormant, moribund or latent cells (e.g. dormant bacterial cells). In addition, the RP-factors of the invention may also exhibit growth-stimulatory activity with respect to growing cells (e.g. growing bacterial cells), and/or may be competent to reduce the lag time of cell (e.g. bacterial cell) cultures. The resuscitation activity (and optionally also the growth-stimulatory activity or lag-time reducing activity) of the RP-factor may be specific for a particular (bacterial) cell (e.g. specific for one or more pathogenic mycobacteria), or may be non-specific. Specificity may be manipulated for example by engineering (e.g. by mutagenesis or chimaerisation, as herein described) of the specificity-determining domain(s) of the RP-factor or by replacement of the signalling domain.

The term "RP-factor" is also used herein in a somewhat broader sense to encompass polypeptides which are expressed by bacteria and which regulate (e.g. promote, trigger, prevent or impair) the growth or multiplication of a cell (the "target cell") by acting as signalling moieties in conjunction with (e.g. by binding to) cognate cellular receptors. Such polypeptides may be referred to herein as bacterial cytokines.

The RP-factors of the invention therefore include bacterial cytokines which may or may not be capable of resuscitating dormant, moribund or latent cells (e.g. dormant bacterial cells) and/or exhibit growth-stimulatory activity with respect to growing cells (e.g. growing bacterial cells). They may or may not also be competent to reduce the lag time associated with the growth of cell (e.g. bacterial cell) cultures. Moreover, some bacterial cytokines which fall within the scope of the term "RP-factor" as defined herein may even prevent or impair the growth of the target cells (particularly where the target cells are eukaryotic (e.g. mammalian) cells).

The RP-factors of the invention may fall into at least two functional classes: aut signalling factors and allosignalling factors. Aut signalling factors act to regulate the growth of the bacterial cell in which they were expressed (i.e. they act as bacterial autocrine factors), while allosignallers act to regulate the growth of other cells (i.e. they act as bacterial paracrine factors). Aut signalling factors therefore act as self-regulators of bacterial cell growth, and may be essential for viability and/or growth. Some RP-factors may function as both auto- and allosignalling cytokines.

Allosignalling factors may exhibit a range of different specificities. Some may act solely on other bacterial cells of the same species as the cell in which they were expressed ("homoactive" factors), while others may act on cells of one or more other species ("heteroactive" factors). Heteroactive factors may exhibit a broad range of specificity: they may act on several different species (for example, in a genus-specific manner), or may be species-specific. Some heteroactive bacterial factors may act on eukaryotic cells, and may be specific for particular cell-types. For example, some heteroactive bacterial cytokines (particularly those produced by certain pathogens) may act on

mammalian cells (e.g. mammalian epithelial, endothelial or immune cells), and may be tissue- or cell-type specific.

Notwithstanding the above explanation, it is postulated that the specificity of at least some RP-factors may be concentration dependent. In these cases, the specificity of any given RP-factor falls within a continuum, so that an aut signalling RP-factor may mediate cross-talk and so exhibit allosignalling activity when present at sufficiently high concentrations. Similarly, allosignalling RP-factors may exhibit homo- or heteroactivity depending on concentration.

The RP-factor may be translocated through the cell membrane, whereafter it may be secreted into the surrounding environment or remain associated with the surface of the cell. Thus, at least two classes of RP-factor may exist: secreted and non-secreted. The secreted RP-factors are characterised by the presence of a secretory signal sequence (the presence of which is readily recognised by those skilled in the art on the basis of the presence of DNA and/or amino acid sequence motifs). The non-secreted RP-factors may be cell-associated or cytosolic factors. Both classes of RP-factor may exist in a single cellular source (e.g. in a single bacterial source). Both classes of RP-factor find application in the invention.

Non-secreted RP-factors may act in at least four different ways: (a) as a membrane-anchored juxtacrine factor mediating a growth regulating signal between two different cells in close physical proximity or contact; and/or (b) as an intercellular signalling moiety upon cleavage by an enzyme (e.g. a convertase, as herein defined) which releases a soluble signalling moiety into the extracellular milieu; and/or (c) as an autocrine factor *via* binding to cognate receptors located on the surface of the cell in which the non-secreted factor is expressed or acting entirely intracellularly; and/or (d) as a cognate receptor for another non-secreted or secreted RP-factor.

Thus, the RP-factors of the invention may include the nine factors identified by the sequences shown in Fig. 1A and the five factors identified by those shown in Fig. 1B, together with their species variants, allelic forms, homologues, derivatives, muteins and corresponding secreted/nonsecreted forms (*vide infra*).

Preferably, the RP-factors of the invention are species variants, allelic forms, homologues, derivatives, muteins and corresponding secreted/nonsecreted forms of any one of the nine factors identified by the sequences shown in Fig. 1A and the five factors identified by those shown in Fig. 1B.

The RP-factors may be synthesised in the form of a precursor which is processed to produce a mature form. Such processing may proceed *via* various intermediate (pro-) forms. Such precursors, intermediate forms and mature proteins are all intended to be covered by the term "RP-factor" as used herein, except where indicated otherwise. As used herein, the term "pro-RP-factor" specifically defines any of various precursors (which may or may not be active) of a mature RP-factor.

The processing may comprise proteolytic cleavage and/or secretion. The precursors may be inactive, and become active on processing as a mature form. The precursors may comprise proteins having secretory leader sequences which are removed during secretion (pre- forms). Such forms are herein referred to as "pre-RP-factor or pre-pro-RP-factors". As explained above, such pre- or prepro- forms are also intended to be covered by the term "RP-factor" as used herein, except where indicated otherwise.

Processing may be attendant on the binding of an RP-factor precursor to a cognate receptor. Such receptors may then directly (or indirectly) cleave the precursor to produce a more mature form of the RP-factor. Such processing may occur as a cascade, involving several receptor-processing complexes, and so ultimately result in the production of a mature RP-factor which then acts as a signalling moiety by binding to a terminal (signal transducing) receptor.

In such processing, the proximal (or intermediate) receptors may function as convertases, and the terminal receptor as a signal transducer. However, a receptor may function as both a convertase and a signal transducer. As used herein, the term "convertase" is intended to define a molecule which binds an RP-factor precursor and (directly or indirectly) processes it to produce a more mature form. They may, for example, have protease activity.

The receptors/convertases discussed above may be disposed at the cell surface (e.g. membrane bound), cytosolic or extracellular.

Preferably, the RP-factor is derived from a bacterium (e.g. a pathogenic bacterium). Particularly preferred are RP-factors derived from high G+C Gram-positive bacteria. However, the inventors have also discovered RP-factor family members in representatives of the low G+C Gram-positive organisms, including *Bacillus subtilis* and clostridia. Thus, RP-factors derived from low G+C Gram-positive bacteria (e.g. pathogenic low G+C Gram-positive bacteria) are also preferred according to the invention. Examples of the latter include: *Streptococcus* spp., *Staphylococcus* spp., *Listeria* spp., *Bacillus* spp., *Clostridium* spp. and *Lactobacillus* spp..

The invention also contemplates homologues, allelic forms, species variants, derivatives, muteins or equivalents of the RP-factors and RP-factor receptors/convertases of the invention.

Preferably, the homologues, derivatives, muteins or equivalents of the RP-factor of the invention have at least 20% identity with any one of the particular amino acid sequences shown in Fig. 1A and 1B.

Particularly preferred are homologues, derivatives, muteins or equivalents of the RP-factor of the invention which have at least 30% identity, for example at least 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% identity with any one of the particular amino acid sequences shown in Fig. 1A and 1B.

The homologues, derivatives, muteins or equivalents of the RP-factor of the invention may have at least 25% homology with any one of the particular amino acid sequences shown in Fig. 1A and 1B.

5 Particularly preferred are homologues, derivatives, muteins or equivalents of the RP-factor of the invention which have at least 30% homology, for example at least 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% homology with any one of the particular amino acid sequences shown in Fig. 1A and 1B.

10 The invention also contemplates chimaeric RP-factors. These are factors which comprise one or more heterologous domains. In this context, a heterologous domain is a portion of an RP-factor which is derived from a different RP-factor to that from which the other domain(s) with which it is associated are derived. Such chimaeric RP-factors find particular utility in applications where the specificity and/or activity of the RP-factor
15 is manipulated or altered.

The invention also contemplates all individual functional domains of the RP-factors of the invention as separate and independent entities.

20 The invention also contemplates recombinant RP-factor. As used herein, the term "recombinant" is intended to define material which has been produced by that body of techniques collectively known as "recombinant DNA technology" (for example, using the nucleic acid, vectors and or host cells described *infra*).

25 Cognate receptors

In some cases, the cognate cellular receptor is a cell surface receptor: in other cases, it is a cytosolic receptor with which the cytokine interacts after uptake by the target cell. The receptors with which the RP-factors and/or bacterial cytokines of the invention
30 interact may share certain structural motifs with the RP-factors/cytokines themselves. In particular, the receptors may contain a ligand binding domain which is structurally similar to the signalling domain of the cognate RP-factor/cytokine.

35 The receptors may also comprise a membrane anchor domain and a wall spanning domain.

Preferably, the cognate receptor comprises a receptor domain as hereinbelow defined and/or a wall spanning domain as hereinbelow defined and/or a membrane anchor.

40 Particularly preferred are cognate receptors comprising the amino acid sequence of MtubZ94752 as shown in Fig. 1A or the amino acid sequence of YabE from *B. subtilis* as shown in Fig. 1B.

45 The cognate receptors may also comprise derivative or equivalent sequences of amino

acid residues which are as defined above but in which amino acids have been added, deleted or substituted (e.g. conservatively substituted), provided that biological activity (e.g. signalling or ligand-binding activity) is substantially retained.

5 The cognate receptors may also comprise derivative or equivalent sequences of amino acid residues which have at least 20% identity or homology with the amino acid sequence of MtubZ94752 as shown in Fig. 1A or the amino acid sequence of YabE from *B. subtilis* as shown in Fig. 1B, for example at least 30% identity or homology, for example at least 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%,
10 90%, 95% or 98% identity or homology therewith.

RP-factor/cognate receptor domain structure

15 The RP-factors of the invention (including the bacterial cytokines as also defined herein) and their cognate receptors may comprise a plurality of discrete domains. These domains may be functionally and/or structurally distinct.

The RP-factors of the invention may be characterised by the presence of at least two functional domains: a secretory signal sequence (which may be wholly or partially
20 absent in the active form of the factor) and a signalling domain. The signalling domain may fall into one of at least two distinct classes described in more detail *infra*.

Many RP-factors also comprise a third functional domain which mediates a physical association with the surface of the target cell (hereinafter referred to as the "localizing domain" and described in more detail *infra*).
25

The RP-factors of the invention may further comprise a specificity-determining domain, which may function in conjunction with the signalling domain.

30 Non-secreted RP-factors may further comprise a wall-spanning domain (described in more detail *infra*) and/or a membrane anchor.

The gross structure and/or amino acid sequence of the aforementioned domains may vary considerably. In particular, the structure of the surface localizing domain may differ
35 according to the structure of the cell-wall of the target cell. For example, the surface localizing domain may fall into one of at least two distinct classes: class I (which may act on peptidoglycan) and class II (which may act on the outer lipid envelope found in mycobacteria).

40 The cognate receptors of the invention may be characterised by the presence of at least two functional domains: a receptor domain and a wall spanning domain. They may also comprise a membrane anchor. The receptor domain may be structurally similar to the signalling domain of the cognate RP-factor (as described in more detail *infra*).

45

Receptor/signalling domain, class I

5 This domain may be associated with RP-factors from high G + C Gram-positive bacteria (such as mycobacteria and *Micrococcus* spp.) and/or their cognate receptors. When present on RP-factors, the domain may be involved in receptor binding, and may for example bind a structurally similar domain on a cognate receptor. Thus, when present as part of an RP-factor of the invention, the domain is termed the "signalling domain", and when present in the cognate receptor, the domain is termed the "receptor domain".

10 The domain may comprise a sequence of amino acid residues, the identity and relative positions of which correspond to those residues indexed by asterisks in any one of the 9 sequences set out in Figure 1A.

15 In preferred embodiments, the domain may comprise a sequence of amino acid residues, the identity and relative positions of which correspond to those residues indexed by asterisks and dots in any one of the 9 sequences set out in Figure 1A.

20 In particularly preferred embodiments, the domain may comprise a sequence of amino acid residues, the identity and relative positions of which correspond to those residues highlighted in bold upper case type in any one of the 9 sequences set out in Figure 1A.

25 In more particularly preferred embodiments, the domain may comprise a sequence of amino acid residues, the identity and relative positions of which correspond to those residues presented in upper case type in any one of the 9 sequences set out in Figure 1A.

30 The domain may also comprise derivative or equivalent sequences of amino acid residues which are as defined above but in which amino acids have been added, deleted or substituted (e.g. conservatively substituted), provided that biological activity (e.g. signalling or ligand-binding activity) is substantially retained.

35 The domain may also comprise derivative or equivalent sequences of amino acid residues which have at least 20% identity or homology with any one of the particular amino acid sequences defined above, for example at least 30% identity or homology, for example at least 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% identity or homology therewith.

Receptor/signalling domain, class II

40 This domain may be associated with RP-factors from low G + C Gram-positive bacteria (such as bacilli and clostridia) and/or their cognate receptors. When present on RP-factors, the domain may be involved in receptor binding, and may for example bind a structurally similar domain on a cognate receptor. Thus, when present as part of an RP-factor of the invention, the domain is termed the "signalling domain", and when present
45 in the cognate receptor, the domain is termed the "receptor domain".

The domain may comprise a sequence of amino acid residues, the identity and relative positions of which correspond to those residues indexed by asterisks in any one of the 5 sequences set out in Figure 1B(B).

5 In preferred embodiments, the domain may comprise a sequence of amino acid residues, the identity and relative positions of which correspond to those residues indexed by asterisks and dots in any one of the 5 sequences set out in Figure 1B(B).

10 In particularly preferred embodiments, the domain may comprise a sequence of amino acid residues, the identity and relative positions of which correspond to those residues highlighted in bold upper case type in any one of the 5 sequences set out in Figure 1B(B).

15 In more particularly preferred embodiments, the domain may comprise a sequence of amino acid residues, the identity and relative positions of which correspond to those residues presented in upper case type in any one of the 5 sequences set out in Figure 1B(B).

20 The domain may also comprise derivative or equivalent sequences of amino acid residues which are as defined above but in which amino acids have been added, deleted or substituted (e.g. conservatively substituted), provided that biological activity (e.g. signalling or ligand-binding activity) is substantially retained.

25 The domain may also comprise derivative or equivalent sequences of amino acid residues which have at least 20% identity or homology with any one of the particular amino acid sequences defined above, for example at least 30% identity or homology, for example at least 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% identity or homology therewith.

30 Wall spanning domain

35 This domain may be associated with non-secreted RP-factors (e.g. cell-associated RP-factors or RP-factors which act as juxtacrine factors) and with the cognate receptors of the RP-factors of the invention. When present, the domain is involved in mediating an interaction with the cell wall such that the RP-factor/receptor as a whole may span it. The wall spanning domain may therefore be bounded by cytosolic and extracellular regions *in vivo*. The domain is often associated with a membrane anchor, the two structural elements acting in concert to maintain the RP-factor/receptor at the cell surface.

40 The domain may comprise a sequence of amino acid residues, the identity and relative positions of which correspond to those residues presented in upper case and indexed by hashes (#) in any one of the 5 sequences set out in Figure 1B(A).

45 In preferred embodiments, the domain may comprise a sequence of amino acid residues,

the identity and relative positions of which correspond to those residues presented in upper case and indexed by hashes and dots in any one of the 5 sequences set out in Figure 1B(A).

5 In particularly preferred embodiments, the domain may comprise a sequence of amino acid residues, the identity and relative positions of which correspond to those residues highlighted in bold upper case type in any one of the 5 sequences set out in Figure 1B(A).

10 In more particularly preferred embodiments, the domain may comprise a sequence of amino acid residues, the identity and relative positions of which correspond to those residues presented in upper case type in any one of the 5 sequences set out in Figure 1B(A).

15 The domain may also comprise derivative or equivalent sequences of amino acid residues which are as defined above but in which amino acids have been added, deleted or substituted (e.g. conservatively substituted), provided that biological activity (e.g. signalling or ligand-binding activity) is substantially retained.

20 The domain may also comprise derivative or equivalent sequences of amino acid residues which have at least 20% identity or homology with any one of the particular amino acid sequences defined above, for example at least 30% identity or homology, for example at least 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% identity or homology therewith.

25 Localizing domain, class I

This domain may be present in secreted RP-factors, and may mediate a physical association with the surface of the target cell by acting to bind peptidoglycan or some other surface component(s). It may therefore act to increase the local concentration of the cytokine at the target cell surface, so promoting activity by increasing the local concentration of RP-factor in the immediate vicinity of the cognate receptor. Localizing domains may therefore be a characteristic feature of allosignalling bacterial cytokines, and may be absent in aut signalling factors or *vice versa*. For example, when present in aut signalling factors, localizing domains may act to retain the factor at or near the cell surface after secretion through the cell membrane.

30 When present, the localizing domain may confer important binding properties on the RP-factor, whereby binding to cognate receptor is biphasic and characterised by a primary (relatively unspecific) association with the cell surface followed by a secondary (relatively highly specific) association with the cognate receptor.

45 The domain may comprise a sequence of amino acid residues, the identity and relative positions of which correspond to those residues indexed by asterisks in any one of the 10 sequences set out in Figure 1C.

In preferred embodiments, the domain may comprise a sequence of amino acid residues, the identity and relative positions of which correspond to those residues indexed by asterisks and dots in any one of the 10 sequences set out in Figure 1C.

5 In particularly preferred embodiments, the domain may comprise a sequence of amino acid residues, the identity and relative positions of which correspond to those residues highlighted in bold upper case type in any one of the 10 sequences set out in Figure 1C.

10 In more particularly preferred embodiments, the domain may comprise a sequence of amino acid residues, the identity and relative positions of which correspond to those residues set out in any one of the 10 sequences set out in Figure 1C.

15 The domain may also comprise derivative or equivalent sequences of amino acid residues which are as defined above but in which amino acids have been added, deleted or substituted (e.g. conservatively substituted), provided that biological activity (e.g. signalling or ligand-binding activity) is substantially retained.

20 The domain may also comprise derivative or equivalent sequences of amino acid residues which have at least 20% identity or homology with any one of the particular amino acid sequences defined above, for example at least 30% identity or homology, for example at least 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% identity or homology therewith.

25 Localizing domain, class II

30 This domain may be present in secreted RP-factors, and may mediate a physical association with the surface of the target cell by acting to bind the outer lipid envelope present in mycobacteria. It may therefore act to increase the local concentration of the cytokine at the target cell surface, so promoting activity by increasing the local concentration of RP-factor in the immediate vicinity of the cognate receptor. Localizing domains may therefore be a characteristic feature of allosignalling bacterial cytokines, and may be absent in aut signalling factors.

35 When present, the localizing domain may confer important binding properties on the RP-factor, whereby binding to cognate receptor is biphasic and characterised by a primary (relatively unspecific) association with the cell surface followed by a secondary (relatively highly specific) association with the cognate receptor.

40 The domain may comprise an alanine plus proline-rich segment, such as one or more of the amino acid motifs 'A', A, B, B', C, 'C, D, D* and D' (any one of which may be tandemly repeated) as set out in Figure 1D.

45 In preferred embodiments, the domain may comprise a sequence of amino acid residues corresponding to residues 158-322 of MtubMTV043 as shown in Figure 1D or to that of residues 45-112 of MtubMTV008 as shown in Figure 1A.

The domain may also comprise derivative or equivalent sequences of amino acid residues which are as defined above but in which amino acids have been added, deleted or substituted (e.g. conservatively substituted), provided that biological activity (e.g. signalling or ligand-binding activity) is substantially retained.

5

The domain may also comprise derivative or equivalent sequences of amino acid residues which have at least 20% identity or homology with any one of the particular amino acid sequences defined above, for example at least 30% identity or homology, for example at least 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% identity or homology therewith.

10

The term "isolated" is used herein to indicate that the factor exists in a physical milieu distinct from that in which it occurs in nature. For example, the isolated factor may be substantially isolated with respect to the complex cellular milieu in which it naturally occurs. The absolute level of purity is not critical, and those skilled in the art can readily determine appropriate levels of purity according to the use to which the factor is to be put.

15

In many circumstances, the isolated factor will form part of a composition (for example a more or less crude extract containing many other proteins and substances), buffer system or pharmaceutical excipient, which may for example contain other components (including other proteins, such as albumin).

20

In other circumstances, the isolated protein may be purified to essential homogeneity, for example as determined by PAGE or column chromatography (for example HPLC or mass spectrometry). In preferred embodiments, the isolated RP-factor of the invention is essentially the sole active RP-factor in a given composition. Particularly preferred are compositions in which an RP-factor (or a particular species, homologue, mutein, derivative or equivalent thereof) is present as the sole active ingredient in a pharmaceutical composition.

25

30

The RP-factor for use in the invention need not be isolated in the sense defined above, however. For example, more or less crude culture supernatants (e.g. "spent" medium) may contain sufficient concentrations of RP-factor for use in several applications. Preferably, such supernatants are fractionated and/or extracted (see below), but in many circumstances they may be used without pretreatment. They are preferably derived from spent media used to culture RP-factor-producing microorganisms (for example, the bacterial sources described *infra*). The supernatants are preferably sterile. They may be treated in various ways, for example by concentration, filtration, centrifugation, spray drying, dialysis and/or lyophilisation. Conveniently, the culture supernatants are simply centrifuged to remove cells/cell debris and filtered.

35

40

Such supernatants find utility in diagnostic kits and methods, for example in the diagnostic kits and methods described *infra*. They also find utility in the recovery from various samples of culturable microorganisms (e.g. from soil, food, marine, freshwater,

45

or tissue samples) or from samples taken from an organism (e.g. a human or animal).

The culture supernatants may also be used as supplements in various culturing substrates, for example in culture or transport media. The culture medium may take any convenient form, such as for example agar plates, broths, slopes, coated dipsticks, coated probes, membranes, coated or filled wells or films. The medium may be a defined or complex medium, and may contain indicator dyes to facilitate identification of cultured microorganisms. Preferably, the medium is suitable for the culturing or transport of bacteria, for example *Mycobacterium* spp..

The term "isolated" as applied to the other materials of the invention (for example, the genes and other nucleic acids encoding the RP-factor and their cognate receptors/convertases) is to be interpreted mutatis mutandis. Thus, as applied to nucleic acid (e.g. RNA or DNA or (structural) genes), the isolated nucleic acid may be present in any of a wide variety of vectors and in any of a wide variety of host cells (or other milieu, such as buffers, viruses or cellular extracts).

The term "family", as applied to the proteins of the invention, is used herein to indicate a group of proteins which share substantial sequence similarities, either at the level of the primary sequence of the proteins themselves, or at the level of the DNA encoding them. The sequence similarities may extend over the entire protein/gene, or may be limited to particular regions or domains. Similarities may be based on nucleotide/amino acid sequence identity as well as similarity (for example, those skilled in the art recognise certain amino acids as similar, and identify differences based on switches of similar amino acids as conservative changes). Some members of a protein family may be related in the sense that they share a common evolutionary ancestry, and such related proteins may herein be referred to as homologues. The members of a protein family do not necessarily share the same biochemical properties or biological functions, though their similarities are usually reflected in common functional features (such as effector binding sites and substrates).

The criteria by which protein families are recognised are well-known in the art, and include computer analysis of large collections of sequences at the level of DNA and protein as well as biochemical techniques such as hybridisation analysis and enzymatic assays (see for example Pearson and Lipman (1988), PNAS USA, 85: 2444).

Thus, the RP-factors of the invention include the factors shown in Fig. 1A and 1B, together with their species variants, allelic forms, homologues, derivatives, muteins and corresponding secreted/nonsecreted forms (*vide infra*). Preferably, the RP-factors of the invention are species variants, allelic forms, homologues, derivatives, muteins and corresponding secreted/nonsecreted forms of any one of the proteins represented in Fig. 1A and Fig. 1B.

The RP-factors may be synthesised in the form of a precursor which is processed to produce a mature form. Such processing may proceed *via* various intermediate (pro-)

forms. Such precursors, intermediate forms and mature proteins are all intended to be covered by the term "RP-factor" as used herein, except where indicated otherwise. As used herein, the term "pro-RP-factor" specifically defines any of various precursors (which may or may not be active) of a mature RP-factor.

5

The processing may comprise proteolytic cleavage and/or secretion. The precursors may be inactive, and become active on processing as a mature form. The precursors may comprise proteins having secretory leader sequences which are removed during secretion (pre- forms). Such forms are herein referred to as "pre-RP-factor or pre-pro-RP-factors". As explained above, such pre- or prepro- forms are also intended to be covered by the term "RP-factor" as used herein, except where indicated otherwise.

10

Processing may be attendant on the binding of an RP-factor precursor to a cognate receptor. Such receptors may then directly (or indirectly) cleave the precursor to produce a more mature form of the RP-factor. Such processing may occur as a cascade, involving several receptor-processing complexes, and so ultimately result in the production of a mature RP-factor which then acts as a signalling moiety by binding to a terminal (signal transducing) receptor.

15

In such processing, the proximal (or intermediate) receptors may function as convertases, and the terminal receptor as a signal transducer. However, a receptor may function as both a convertase and a signal transducer. As used herein, the term "convertase" is intended to define a molecule which binds an RP-factor precursor and (directly or indirectly) processes it to produce a more mature form. They may, for example, have protease activity.

20

25

The receptors/convertases discussed above may be disposed at the cell surface (e.g. membrane bound), cytosolic or extracellular.

30

Preferably, the RP-factor is derived from a bacterium (e.g. a pathogenic bacterium). Particularly preferred are RP-factors derived from high G + C Gram-positive bacteria.

35

The term "derived from" as applied to a defined source is intended to define not only a source in the sense of it being the *physical* origin for the material, but also to define material which has structural and/or functional characteristics which correspond to those of material which does originate from the reference source. Thus, a protein "derived from" a given source need not necessarily have been purified from that source.

40

45

The term "high G + C Gram-positive bacterium" is a term of art defining a particular class of evolutionarily related bacteria. The class includes *Micrococcus* spp. (e.g. *M. luteus*), *Mycobacterium* spp. (for example a fast- or slow-growing mycobacterium, e.g. *M. tuberculosis*, *M. leprae*, *M. smegmatis* or *M. bovis*), *Streptomyces* spp. (e.g. *S. rimosus* and *S. coelicolor*) and *Corynebacterium* spp. (e.g. *C. glutamicum*). Preferred according to the invention are RP-factors/cognate receptors/convertases derived from mycobacteria ("mycobacterial RP-factors/RP-factor receptors/convertases").

The invention also contemplates homologues, allelic forms, species variants, derivatives, muteins or equivalents of the RP-factors and RP-factor receptors/convertases of the invention.

5 The term "homologue" is used herein in two distinct senses. It is used *sensu stricto* to define the corresponding protein from a different organism (i.e. a species variant), in which case there is a direct evolutionary relationship between the protein and its homologue. This may be reflected in a structural and functional equivalence, the protein and its homologue performing the same role in each organism.

10

The term is also used herein *sensu lato* to define a protein which is structurally *similar* (i.e. not necessarily related and/or structurally and functionally equivalent) to a given (reference) RP-factor. In this sense, homology is recognised on the basis of purely structural criteria by the presence of amino acid sequence identities and/or conservative amino acid changes (as set out by Dayhoff *et alia*, *Atlas of protein structure* vol. 5, National BioMed Fd'n, Washington D.C., 1979).

15

For the purposes of the invention, homologues may be recognised as those proteins the corresponding DNAs of which are capable of specifically or selectively cross-hybridising, or which can cross-hybridise under selective, appropriate and/or appropriately stringent hybridisation conditions.

20

The term "selectively or specifically (cross)hybridisable" in this context indicates that the sequences of the corresponding ssDNAs are such that binding to a unique (or small class) of homologous sequences can be obtained under more or less stringent hybridisation conditions. This method of the invention is not dependent on any particular hybridisation conditions, which can readily be determined by the skilled worker (e.g. by routine trial and error or on the basis of thermodynamic considerations).

25

30 Preferably, the homologues, derivatives, muteins or equivalents of the RP-factor of the invention have at least 20% identity with any one of the particular amino acid sequences shown in Fig. 1A or Fig. 1B.

35

Particularly preferred are homologues, derivatives, muteins or equivalents of the RP-factor of the invention which have at least 30% identity, for example at least 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% identity with any one of the particular amino acid sequences shown in Fig. 1A or Fig. 1B.

40

The homologues, derivatives, muteins or equivalents of the RP-factor of the invention may have at least 25% homology with any one of the particular amino acid sequences shown in Fig. 1A or Fig. 1B.

45

Particularly preferred are homologues, derivatives, muteins or equivalents of the RP-factor of the invention which have at least 30% homology, for example at least 35%,

40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% homology with any one of the particular amino acid sequences shown in Fig. 1A or Fig. 1B.

5 The term "derivative" as applied herein to the proteins (e.g. the RP-factors or RP-factor receptors/convertases) of the invention is used to define proteins which are modified versions of the proteins of the invention. Such derivatives may include fusion proteins, in which the proteins of the invention have been fused to one or more different proteins or peptides (for example an antibody or a protein domain conferring a biochemical
10 activity, to act as a label, or to facilitate purification).

The derivatives may also be products of synthetic processes which use a protein of the invention as a starting material or reactant.

15 The term "mutein" is used herein to define proteins that are mutant forms of the proteins of the invention, i.e. proteins in which one or more amino acids have been added, deleted or substituted. The muteins of the invention therefore include fragments, truncates and fusion proteins (e.g. comprising fused immunoglobulin, receptor, convertase or enzyme moieties).

20 The muteins of the invention also include proteins in which mutations have been introduced which effectively promote or impair one or more activities of the protein, for example mutations which promote or impair the function of a receptor, a recognition sequence or an effector binding site.

25 Muteins may be produced by any convenient method. Conveniently, site-directed mutagenesis with mutagenic oligonucleotides may be employed using a double stranded template (pBluescript KS II construct containing the RP-factor or RP-factor receptor/convertase gene), (e.g. Chameleon™ or QuikChange™ - Stratagene™). After
30 verifying each mutant derivative by sequencing, the mutated gene is excised and inserted into a suitable vector so that the modified protein can be over-expressed and purified.

35 Preferred mutant forms are truncates consisting (or consisting essentially) of the RP-factor signalling domain or the RP-factor specificity-determining factor, or of the ligand binding domain of the RP-factor receptor, or combinations of two or more of the foregoing.

40 The invention also contemplates chimaeric RP-factors. These are factors which comprise one or more heterologous domains. In this context, a heterologous domain is a portion of an RP-factor which is derived from a different RP-factor to that from which the other domain(s) with which it is associated are derived. Such chimaeric RP-factors find particular utility in applications where the specificity and/or activity of the RP-factor is manipulated or altered.

45

Useful in the construction of such chimaeric RP-factors are DNA fragments or cassettes consisting essentially of DNA encoding selected domains (for example, the signalling domain or the specificity-determining domain), the fragment or cassette optionally being bounded by one or more restriction endonuclease cleavage sites or cloning sites. The invention also contemplates concatenated domain cassettes, as well as mutant RP-factor structural genes which have cloning sites (e.g. one or more restriction endonuclease cleavage sites) located in one or more interdomain regions.

The term equivalent as used herein and applied to the materials of the invention defines materials (e.g. proteins, DNA etc.) which exhibit substantially the same functions as those of the materials of the invention while differing in structure (e.g. nucleotide or amino acid sequence). Such equivalents may be generated for example by identifying sequences of functional importance (e.g. by identifying conserved or canonical sequences or by mutagenesis followed by functional assay), selecting an amino acid sequence on that basis and then synthesising a peptide based on the selected amino acid sequence. Such synthesis can be achieved by any of many different methods known in the art, including solid phase peptide synthesis (to generate synthetic peptides) and the assembly (and subsequent cloning) of oligonucleotides.

The homologues, fragments, muteins, equivalents or derivatives of the proteins of the invention may also be defined *inter alia* as those proteins which cross-react with antibodies to the proteins of the invention, and in particular which cross-react with antibodies directed against any of the specific proteins shown Fig. 1A or Fig. 1B.

The invention also contemplates all individual functional domains of the RP-factors of the invention as separate and independent entities.

The invention also contemplates recombinant RP-factor. As used herein, the term "recombinant" is intended to define material which has been produced by that body of techniques collectively known as "recombinant DNA technology" (for example, using the nucleic acid, vectors and or host cells described *infra*).

The invention also contemplates a pharmaceutical composition (e.g. a vaccine) comprising the RP-factor or RP-factor receptor/convertase (or homologue, species variant, allelic form, derivative, mutein or equivalent thereof) of the invention.

A pharmaceutical composition is a solid or liquid composition in a form, concentration and level of purity suitable for administration to a patient (e.g. a human or animal patient) upon which administration it can elicit the desired physiological changes. The vaccines of the invention may include any suitable adjuvant (e.g. Freund's adjuvant, BCG or BCG extracts).

In another aspect, the invention relates to a pharmaceutical composition comprising the material of the invention which is: (a) for use in therapy (e.g. immunotherapy), diagnosis or prophylaxis; and/or (b) in a pharmaceutical excipient, a unit dosage form or in a form

suitable for local or systemic administration.

In another aspect, the invention relates to an antibody (or antibody derivative) specific for the RP-factor (or homologue, derivative, mutein or equivalent thereof) of the invention.

The antibody is preferably in a form suitable for use in therapy (e.g. immunotherapy), diagnosis or prophylaxis; and/or formulated in a pharmaceutical excipient, a unit dosage form or in a form suitable for local or systemic administration. The antibody may be labelled and/or immortalised and/or conjugated to another moiety, and such embodiments find particular utility in diagnostic applications.

According to another aspect of the invention there is provided an isolated or recombinant RP-factor receptor.

The receptor/convertase may be derived from any of the sources hereinbefore described, for example from a bacterial source (e.g. a pathogenic bacterial source). Such sources include high G + C Gram-positives, *Micrococcus* spp. (e.g. *M. luteus*); or *Mycobacterium* spp. (for example a fast- or slow-growing mycobacterium, e.g. *M. tuberculosis*, *M. leprae*, *M. smegmatis* or *M. bovis*); or *Streptomyces* spp. (e.g. *S. rimosus* and *S. coelicolor*); or *Corynebacterium* spp. (e.g. *C. glutamicum*).

The invention also contemplates homologues, derivatives, muteins or equivalents of the receptors/convertases of the invention, as well as recombinant RP-factor receptors/convertases (as hereinbefore defined).

The invention also contemplates a pharmaceutical composition (e.g. a vaccine) comprising the receptor/convertase (or homologue, derivative, mutein or equivalent thereof) of the invention.

Preferably, the receptor/convertase (or homologue, derivative, mutein or equivalent thereof) or pharmaceutical composition is: (a) for use in therapy (e.g. immunotherapy), diagnosis or prophylaxis; and/or (b) in a pharmaceutical excipient, a unit dosage form or in a form suitable for local or systemic administration.

Also contemplated is an antibody (or antibody derivative) specific for the receptor/convertase (or homologue, derivative, mutein or equivalent thereof) of the invention. The antibody may be: (a) for use in therapy (e.g. immunotherapy), diagnosis or prophylaxis; and/or (b) in a pharmaceutical excipient, a unit dosage form or in a form suitable for local or systemic administration.

Also contemplated is an RP-factor antagonist or inhibitor.

Preferably, the antagonist or inhibitor comprises: (a) the antibody of the invention; and/or (b) the receptor/convertase of the invention; and/or (c) an RP-factor mutein

comprising an RP-factor specificity-determining domain, which for example lacks a functional signalling domain. The receptor may function as an antagonist or inhibitor if administered in soluble form, where it may act as a sink for soluble RP-factor.

5 Preferably, modified receptors consisting of the receptor domain (and lacking the membrane anchor and wall spanning domain) are used as inhibitors or antagonists. Such derivatives may exhibit higher solubility.

10 The antagonist or inhibitor of the invention is preferably: (a) for use in therapy (e.g. immunotherapy), diagnosis or prophylaxis; and/or (b) in a pharmaceutical excipient, a unit dosage form or in a form suitable for local or systemic administration.

15 Also contemplated by the invention is an RP-factor agonist, activator or mimetic. Preferably, the agonist, activator or mimetic comprises: (a) the RP-factor receptor/convertase antibody as herein described; and/or (b) an RP-factor mutein comprising (or consisting of) an RP-factor specificity-determining domain; and/or (c) an RP-factor mutein comprising (or consisting of) an RP-factor signalling domain; and/or (d) operably coupled combinations of any of (a)-(c).

20 The agonist, activator or mimetic may be: (a) for use in therapy (e.g. immunotherapy), diagnosis or prophylaxis; and/or (b) formulated in a pharmaceutical excipient, a unit dosage form, in a form suitable for local or systemic administration or in admixture with an antibiotic.

25 Preferably, the agonist, activator or mimetic may be for use in adjunctive therapy (for example formulated or presented in combination with an antimicrobial agent, e.g. an antibiotic).

30 The invention also contemplates isolated nucleic acid encoding the RP-factor (or homologue, derivative, allelic form, species variant, mutein or equivalent thereof) or RP-factor receptor/convertase (or homologue, derivative, allelic form, species variant, mutein or equivalent thereof) of the invention. The nucleic acids of the invention therefore embrace DNA having any sequence so long as it encodes the proteins of the invention. It will be appreciated by those skilled in the art that as a result of degeneracy in the genetic code, any particular amino acid sequence of the invention may be encoded by many different sequences. Thus, the nucleic acid sequence may be selected or optimised, e.g. with respect to the codon usage in any particular host cell.

40 The invention also contemplates vectors (e.g. an expression vector) comprising the nucleic acid of the invention. The nature of the vector is not critical to the invention. Any suitable vector may be used, including plasmid, virus, bacteriophage, transposon, minichromosome, liposome or mechanical carrier.

45 The expression vectors of the invention are DNA constructs suitable for expressing DNA which encodes the desired protein product (e.g. RP-factor or RP-factor receptor) which may include: (a) a regulatory element (e.g. a promoter, operator, activator, repressor

and/or enhancer), (b) a structural or coding sequence which is transcribed into mRNA and (c) appropriate transcription, translation, initiation and termination sequences. They may also contain sequence encoding any of various tags (e.g. to facilitate subsequent purification of the expressed protein, such as affinity (e.g. His) tags).

5

Particularly preferred are vectors which comprise an expression element or elements operably linked to the DNA of the invention to provide for expression thereof at suitable levels. Any of a wide variety of expression elements may be used, and the expression element or elements may for example be selected from promoters, enhancers, ribosome binding sites, operators and activating sequences. Such expression elements may comprise an enhancer, and for example may be regulatable, for example being inducible (via the addition of an inducer).

10

As used herein, the term "operably linked" refers to a condition in which portions of a linear DNA sequence are capable of influencing the activity of other portions of the same linear DNA sequence. For example, DNA for a signal peptide (secretory leader) is operably linked to DNA for a polypeptide if it is expressed as a precursor which participates in the secretion of the polypeptide; a promoter is operably linked to a coding sequence if it controls the transcription of the sequence; a ribosome binding site is operably linked to a coding sequence if it is positioned so as to permit translation.

15

20

The vector may further comprise a positive selectable marker and/or a negative selectable marker. The use of a positive selectable marker facilitates the selection and/or identification of cells containing the vector.

25

Also contemplated by the invention are host cells comprising the vector of the invention. Any suitable host cell may be used, including prokaryotic host cells (such as *Escherichia coli*, *Streptomyces* spp. and *Bacillus subtilis*) and eukaryotic host cells.

30

35

In another aspect, the invention provides a culture or transport medium comprising the RP-factor (or homologue, derivative, mutein or equivalent thereof) of the invention. The culture medium may take any convenient form, such as for example agar plates, broths, slopes, coated dipsticks, coated probes, membranes, coated or filled wells or films. The medium may be a defined or complex medium, and may contain indicator dyes to facilitate identification of cultured microorganisms. Preferably, the medium is suitable for the culturing or transport of bacteria, for example *Mycobacterium* spp. *Streptomyces* spp. and *Corynebacterium* spp.

40

The invention also contemplates a nucleic acid probe comprising nucleic acid complementary to the nucleic acids of the invention. Such probes are preferably selectively hybridisable with nucleic acid encoding the proteins (e.g. the RP-factors of RP-factor receptors/convertases) of the invention. They are conveniently single stranded DNA or RNA probes.

45

The invention also contemplates a diagnostic kit comprising the factor (or homologue,

derivative, mutein or equivalent thereof), receptor, antibody, probe or culture medium of the invention.

5 In another aspect, the invention contemplates antisense DNA corresponding to the nucleic acid encoding the RP-factor or RP-factor receptor/convertase of the invention.

10 The invention also contemplates a process for producing an antimicrobial drug comprising the steps of: (a) providing an RP-factor receptor; (b) providing candidate drugs; (c) screening the candidate drugs by contacting the RP-factor receptor/convertase with one of the candidate drugs and determining the affinity of the candidate drug for the RP-factor receptor, wherein the affinity is an index of antimicrobial activity, and optionally (d) synthesising or purifying a drug having antimicrobial activity on the basis of the identity of the candidate drug screened in step (c).

15 Preferably, the process for producing an antimicrobial drug comprises the steps of: (a) providing an RP-factor receptor/convertase; (b) providing a candidate drug; (c) providing an RP-factor; (d) screening the candidate drugs by contacting the RP-factor receptor/convertase with one of the candidate drugs in the presence of the RP-factor, and then determining the ability of the candidate drug to compete non-productively with the RP-factor for binding to the RP-factor receptor, wherein the competitive binding ability is an index of antimicrobial activity, and optionally (e) synthesising or purifying a drug having antimicrobial activity on the basis of the identity of the candidate drug screened in step (d).

20 25 The invention also covers an antimicrobial drug produced by (or obtainable by) the processes of the invention, and also derivatives thereof.

30 Also contemplated by the invention is a method for determining the microbiological quality of a product (e.g. a foodstuff, pharmaceutical preparation or medical product) comprising the step of contacting a sample of the product with an RP-factor (for example, an RP-factor as hereinbefore defined). In such methods, the RP-factor preferably forms part of a nutrient composition (e.g. a plate, broth, film or dipstick).

35 In another aspect, the invention relates to a method of culturing bacterial (e.g. mycobacterial) cells, comprising the step of incubating the cells in a culture medium containing an RP-factor (for example, an RP-factor as hereinbefore defined).

40 Also contemplated by the invention is an *ex vivo* method of diagnosis, comprising the step of contacting a biological sample with an RP-factor (for example, an RP-factor as hereinbefore defined).

45 The diagnostic method of the invention preferably includes the step of incubating the culture or transport medium of the invention to permit growth of cells in the biological sample (e.g. bacterial cells).

Also contemplated by the invention is a method of: (a) stimulating the growth of a microorganism; and/or (b) resuscitating a dormant, moribund or latent microorganism; comprising the step of contacting the microorganism with an RP-factor (for example, an RP-factor as hereinbefore defined).

5

The invention also contemplates a process for producing the recombinant RP-factor or RP-factor receptor/convertase of the invention comprising the steps of: (a) culturing the host cell of the invention, and (b) purifying the factor or receptor/convertase from the cultured host cells (e.g. from a culture supernatant or cell fraction).

10

Also contemplated by the invention is a process for producing the recombinant RP-factor or receptor/convertase of the invention comprising the steps of: (a) probing a gene library with a nucleic acid probe which is selectively hybridisable with the cognate structural gene to produce a signal which identifies a gene that selectively hybridises to the probe; (b) expressing the gene identified in step (a) (for example by cloning into a host cell, e.g. according to the process as hereinbefore defined) to produce the factor or receptor.

15

Also covered is a recombinant RP-factor or receptor/convertase obtainable by the above-described process.

20

Medical applications

The invention permits the isolation, synthesis and rational design of a wide range of novel medicaments and pharmaceuticals for use in therapy, prophylaxis and diagnosis.

25

The various forms of therapy, prophylaxis and diagnosis in which the materials of the invention find application may involve changing, breaking or perturbing the resuscitation (RP-factor) signal transduction pathway of one or more infecting pathogens.

30

Thus, the materials of the invention find general application as antimicrobial agents, for example as antibacterial agents. They may therefore be used in the treatment, prophylaxis or diagnosis of microbial (e.g. bacterial) infections, particularly those infections associated with latency (e.g. mycobacterial infections).

35

Thus, the invention may for example be used to prevent, reduce or interfere with: (a) the resuscitation of a latent (or dormant) pathogen, and/or (b) the growth of a pathogen, and/or (c) the multiplication and spread of a pathogen; and/or (d) the activation of a latent infection (for example a latent bacterial (e.g. mycobacterial) infection).

40

In general, the materials of the invention may be used to treat conditions in which changing, breaking or perturbing the resuscitation (RP-factor) signal transduction pathway or blockading the RP-factor receptor/convertase associated with an infecting pathogen is indicated.

45

Particularly useful materials for use in such therapies/prophylactic methods include RP-factor antagonists or inhibitors. Such antagonists or inhibitors may comprise antibodies to the RP-factor or to the RP-factor receptor/convertase as herein defined; the RP-factor receptor/convertase of the invention; an RP-factor mutein, e.g. which comprises an altered RP-factor specificity-determining domain and/or which lacks a functional signalling domain.

RP-factor antibodies act to sequester and ultimately eliminate endogenous RP-factors in a patient bearing a latent microbial infection.

RP-factor receptor antibodies bind non-productively to the receptors associated with the infecting pathogen. Antibodies to the convertase inactivate (e.g. by steric inhibition) the convertase activity and so prevent maturation of the RP-factor. The antibodies may therefore competitively inhibit the binding of endogenous RP-factor to the receptors/convertases associated with the infecting pathogen. Alternatively, they may bind with high affinity (and/or essentially irreversibly) to the RP-factor receptors/convertases and so block RP-factor-ligand binding or RP-factor maturation. A similar activity is displayed by the RP-factor muteins having altered specificity and/or signalling activity.

In either case, the RP-factor-RP-receptor/convertase binding required for resuscitation of latent pathogens, growth of the pathogen and/or progression of the disease state is perturbed, reduced or abolished.

RP-factor receptors for use as therapeutics in such methods are uncoupled from the signal transduction pathway with which they are normally associated. Thus, they are preferably free (i.e. in soluble or dispersible) form and/or not membrane bound. In this way, effective circulating or systemic concentrations of the free RP-factor receptor can be established and maintained in a patient. In this form, the RP-factor receptors act as RP-factor sinks, and titrate out (and preferably ultimately eliminate) endogenous RP-factors in a patient bearing a latent microbial infection. The receptors therefore reduce or prevent activation of the (latent) pathogen and/or stimulation of pathogen growth, so slowing or halting the progression of the infection.

In another aspect, the invention may be used to resuscitate or assist in resuscitating (or activate or assist in activating) a latent (dormant) pathogenic microbe *in vivo* thereby to potentiate adjunctive antimicrobial therapy. The adjunctive antimicrobial therapies for use in such applications are those which depend for full efficacy on a non-latent or active (e.g. growing or replicating) target pathogen population (for example adjunctive therapies based on certain types of antibiotic). Thus, the materials of the invention may act synergistically with various antimicrobial compounds in antimicrobial therapy.

In a preferred embodiment, the invention is used to potentiate the antimicrobial therapy of tuberculosis, for example involving co-administration of one or more of isoniazid, rifampicin, pyrazinamide and/or ethambutol (or streptomycin).

Particularly useful materials for use in such therapies include for example the RP-factors of the invention, RP-factor agonists, activators and mimetics. Such agonists, activators or mimetics may comprise: the RP-factor receptor antibodies as hereinbefore described; the RP-factor convertase as hereinbefore defined; an RP-factor mutein comprising (or consisting of) an RP-factor specificity-determining domain; an RP-factor mutein comprising (or consisting of) an RP-factor signalling domain; and/or operably coupled combinations thereof.

The RP-factor receptor antibodies for use in such methods are those which serve to trigger an efferent signal transduction pathway at the RP-factor receptor. They may therefore act as RP-factor mimetics, breaking latency/dormancy and acting to resuscitate the pathogen.

Particularly useful in such methods are mutant RP-factors having altered specificity (e.g. in which the specificity-determining domain has been mutated or modified). Such mutant RP-factors may be active against a broad range of pathogens (e.g. against substantially all pathogenic or infective mycobacteria) or targeted against specific pathogens (for example, *M. tuberculosis* and *M. leprae*).

The antibodies, RP-factors, receptors and convertases discussed above may be administered directly or *via* a live vaccine vehicle. Such live vaccines vehicles comprise microorganisms which have been genetically engineered to express (and preferably secrete) the therapeutically active antibodies, RP-factors, receptors and convertases of the invention *in vivo*.

The invention therefore finds application in the treatment of a wide variety of microbial infections, and finds particular application in the treatment of latent microbial (e.g. bacterial) infections.

In preferred embodiments, the invention finds application in the treatment of actinomycete or mycobacterial infections, for example those involving *M. tuberculosis*, *M. leprae*, *M. bovis*, *M. kansasii* and *M. avium*.

Other infections which may be treated according to the invention include those involving *Corynebacterium* spp. (including *Corynebacterium diphtheriae*), *Tropheryma whippelii*, *Nocardia* spp. (including *Nocardia asteroides* and *Nocardia brasiliensis*), *Streptomyces* spp. (including *Streptomyces griseus*, *Streptomyces paraguayensis* and *Streptomyces somaliensis*), *Actinomadura* spp., *Nocardiosis* spp., *Rhodococcus* spp., *Gordona* spp., *Tsukamurella* spp. and *Oerskovia* spp. as well as other pathogenic organisms from the group referred to as high G + C Gram-positive bacteria. Other infections which may be treated include those involving pathogenic low G + C Gram-positive bacteria (e.g. *Streptococcus* spp., *Staphylococcus* spp., *Listeria* spp., *Bacillus* spp., *Clostridium* spp. and *Lactobacillus* spp.).

The invention may also be embodied in various vaccines or immunotherapeutic agents.

Such vaccines or agents target one or more elements of the RP-factor mediated signal transduction pathway described herein (and in particular, the RP-factor or RP-factor receptors/convertases themselves). Thus, the RP-factors may be administered as part of a vaccine or immunotherapeutic composition to elicit an immune response directed against endogenous RP-factor in the patient, so reducing, preventing activation of the pathogen and so slowing or halting the progression of the infection.

Alternatively (or in addition), the RP-factor receptors/convertases may be administered as part of a vaccine or immunotherapeutic composition to elicit an immune response directed against receptors for pathogen-borne RP-factor in the patient. In this way, cellular and/or humoral immune responses may be stimulated against the pathogen(s) and/or activation of a latent pathogen (or its continued growth or multiplication) *via* the RP-factor signal transduction pathway may be reduced or prevented, so slowing or halting the progression of the infection.

The invention also finds application in the preparation of live vaccines: attenuated microbial strains can be constructed in which the gene(s) encoding (or regulating the expression or activity of) one or more RP-factors are mutated. Such attenuated vaccines may be based on mutant strains of actinomycetes, mycobacteria (for example *M. tuberculosis*, *M. leprae*, *M. bovis* (such as *M. bovis* BCG), *M. kansasii* and *M. avium*), *Corynebacterium* spp. (including *Corynebacterium diphtheriae*), *Tropheryma whippellii*, *Nocardia* spp. (including *Nocardia asteroides* and *Nocardia brasiliensis*), *Streptomyces* spp. (including *Streptomyces griseus*, *Streptomyces paraguayensis* and *Streptomyces somaliensis*), *Actinomadura* spp., *Nocardiopsis* spp., *Rhodococcus* spp., *Gordona* spp., *Tsukamurella* spp. and *Oerskovia* spp. as well as other pathogenic organisms from the group referred to as high G + C Gram-positive bacteria.

Particularly useful in such attenuated vaccines are strains bearing mutated RP-factor-encoding genes. Such mutations may be frameshift, deletion, insertion and/or substitution mutations. In preferred embodiments the mutations are null mutations (e.g. non-reverting null mutations), and may prevent growth of the microbe (i.e. "attenuate" it). In other embodiments the mutations may result in the expression of mutant RP-factors having altered specificity (e.g. in which the specificity-determining domain has been mutated or modified) and/or which lack a functional signalling domain. Such mutant RP-factors may bind with high affinity (and/or essentially irreversibly) and non-productively to the RP-factor receptors/convertases and so block RP-factor-ligand binding or RP-factor maturation. The attenuated microbial strains of the invention may also bear mutations in other genes (for example, in other genes essential to growth), and may also bear one or more genetic marker elements.

Biotechnological applications

It is widely recognised that the great majority (probably well in excess of 99%) of soil organisms have not yet been cultured. Hitherto uncultured organisms are also expected to exist in other sources. The present invention may be used to permit the recovery of

such organisms by culture from any source. Thus, the invention provides a way of unlocking an immense reservoir of biodiversity that is known to exist, but is presently inaccessible.

5 Thus, the present invention provides an unprecedented resource from which libraries of potentially useful microorganisms and biomolecules can be generated. Such libraries can then be used in screening methods to search for medically or industrially useful products.

10 Thus, in another aspect the invention provides a process for producing a library of biomolecules comprising the steps of: (a) providing a sample (e.g. a soil, marine, food, freshwater, tissue or organism-derived); (b) incubating the sample in a culture medium comprising an RP-factor (for example, an RP-factor as defined in the preceding claims or a culture supernatant comprising an RP-factor) to produce a microbial culture; and (c)
15 isolating microorganisms from the culture of step (b).

The process may further comprise the step of screening the isolated microorganisms for those which elaborate one or more biomolecules of interest (for example a metabolite, enzyme, antibiotic (e.g. antiviral, antibacterial or antifungal agent) or toxin).

20 Also contemplated is a biomolecule produced by (or obtainable by) the above process, or a derivative thereof.

In another aspect, the invention provides a process for producing a library of
25 microorganisms (e.g. bacteria) comprising the steps of: (a) providing a sample (e.g. a soil, marine, food, freshwater, tissue or organism-derived sample); (b) incubating the sample in a culture medium comprising an RP-factor (for example, an RP-factor as defined in the preceding claims or a culture supernatant comprising an RP-factor) to produce a microbial culture; (c) isolating microorganisms from the culture of step (b).

30 Also contemplated is a microbe produced by (or obtainable by) the above process, or a derivative (e.g. mutant) thereof.

Exemplification

35 The invention will now be described in more detail with reference to several Examples. These are for exemplary purposes only and are not intended to limit the invention in any way.

Explanation of the Figures

40 Figure 1: Part A. Multiple sequence alignment of the predicted amino-acid sequences of RP-factor-like gene products from *M. luteus*, *M. tuberculosis*, *M. leprae* and *Streptomyces coelicolor*. Proteins similar to the RP-factor are derived from *M. tuberculosis* (accession nos. U38939,
45

nt 2406-2765, and Z81368, nt 33932-34396) and *M. leprae* (accession nos. L01095, nt 12292-12759, and L04666, nt 25446-24921). The DNA sequences of interest in accession Z81368 are also encompassed by accession AD000010. N-terminal residues corresponding to predicted Gram-positive signal sequences are underlined. The *M. leprae* L04666 sequence may also contain a short, 32 aa signal peptide.

Part B. Multiple sequence alignment of gene products related to YabE of *Bacillus subtilis*. The alignment is given in two parts (A and B), with aligned residues in upper case. Those residues which are conserved (or conservatively substituted) in two or more sequences are in bold. In Part A, perfectly conserved residues are marked with a hash (#) and conservative substitutions with a dot (.). Cperfring is an incomplete ORF1 from *Clostridium perfringens* (Acc. No. UO4966); Caceto506 is an incomplete ORF from contig 506, *Clostridium acetobutylicum* genome sequencing project. YocH from *B. subtilis* and YabE from *B. subtilis* are YocH and YabE predicted gene products from the *B. subtilis* genome sequencing project (Acc. Nos. BG13521 and P37456).

Part C. Alignment of the RP-factor C-terminal domain with known and hypothetical wall-associated proteins from other organisms. Perfectly conserved residues are marked with an asterisk, those conserved in at least 7 sequences are marked with a dot (.).

Part D. Motifs in the C-terminus (residues 158-322) of MtubMTV043.

Part E. Alignment between the predicted amino acid sequence of the *M. luteus* RP-factor and p60 proteins from *Listeria* spp. Many of the residues that are conserved in the alignment between the C-terminal portion of the *M. luteus* RP-factor (residues 125-220) and the *L. monocytogenes* EGD p60 protein (residues 158-245), are also conserved in the p60 protein from six other *Listeria* spp.

Figure 2: Part A. The sequence of the RP-factor-encoding gene and its predicted product. The nucleotide sequence is in lower case with PCR primers in bold. The predicted protein sequence is in upper case bold (single letter code). Protein and peptide microsequence data used for oligonucleotide design are in upper case italics.

Part B. The sequence of a 299 base pair DNA fragment encoding part of an RP-factor from *Streptomyces coelicolor*. The deduced amino acid sequence is given below the DNA sequence using the single letter amino acid code.

Figure 3: The elution profile of the resuscitation activity. Fractions eluted from the DEAE-sepharose column (see Materials and Methods) with 0.25 M KCl were applied to a Mono Q column which was developed with a 20ml linear gradient from 0.08 to 0.28 M KCl in 10 mM Tris-Cl buffer supplemented by 10% glycerol, pH 7.4. 10 ml of a diluted

suspension of starved cells (CFU 3.10^6 cells.ml⁻¹, total count $1.2.10^9$ cells.ml⁻¹) were added to 200 ml of LMM supplemented with 0.5 % w/v lactate and 0.05% yeast extract containing of 2 μ l of each fraction in 5-10 replicates in the Bioscreen instrument. For details see Materials and Methods. **A:** absorbance at 280nm and magnitude of KCl concentration. **B:** resuscitation activity. **C:** SDS-PAGE profile of the fractions following DEAE-cellulose and Mono Q chromatography. Lanes : 1, markers (94,000, 67,000, 43,000, 30,000, 20,100, 14,400); 2, fraction from DEAE-cellulose column; 3, purified preparation (fraction number 8 from the Mono Q -column). **D:** Reduction of apparent lag phase of viable cells. 10 μ l of a diluted suspension of viable, stationary phase cells (viable count 20 cells) was added to 200 μ l of LMM supplemented with 0.5 % w/v L-lactate and containing 2 μ l of each fraction (from a different experiment to that shown in parts A and B) in 5-10 replicates in the Bioscreen instrument. The apparent lag phase was estimated by extrapolating the exponential growth line to the abscissa.

Figure 4: Effect of purified RP-factor on *M. luteus*.

A. Concentration dependence of RP-factor activity for resuscitation: resuscitation of dormant cells with different concentrations of RP-factor. 10 μ l of a diluted suspension of starved cells (CFU 3.10^6 cells.ml⁻¹, total count 5.10^9 cells.ml⁻¹) was added to 200 μ l of LMM supplemented with 0.5 % w/v L-lactate, 0.05% yeast extract and RP-factor in concentrations shown in 5-10 replicates in the Bioscreen instrument. For details see Materials and Methods.

B. Growth of washed cells. Stationary phase cells of *M. luteus* grown in LMM were washed five times by suspension and centrifugation in LMM from which lactate had been omitted. Bacteria were finally suspended in the same medium by repeatedly passing them through a syringe, diluted and inoculated into a 20 ml flask containing LMM or LMM plus 31 pM RP-factor. The initial cell density was 250 viable cells per ml and incubation was at 30°C with intensive shaking. Growth was monitored by plating 0.1ml samples on plates containing broth E solidified with agar.

Figure 5: Detection of RP-factor-like genes in *Micrococcus luteus*, *Mycobacterium smegmatis* and *Streptomyces rimosus*.

	Part A	Part B	Part C
	<i>M. luteus</i>	<i>M. luteus</i>	
Lane 1	λ BstEII	λ PstI	λ PstI
Lane 2	ClaI	XhoI	<i>S. rimosus</i> XhoI
Lane 3	SaI	StuI	<i>S. rimosus</i> StuI
Lane 4	SacII	SmaI	<i>S. rimosus</i> SmaI
Lane 5	PstI	PvuII	<i>S. rimosus</i> PvuII
Lane 6	NcoI	PstI	<i>S. rimosus</i> PstI
Lane 7	NheI	KpnI	<i>S. rimosus</i> BamHI
Lane 8	MluI	BamHI	<i>M. smegmatis</i> XhoI
Lane 9	AatII	λ PvuII	<i>M. smegmatis</i> StuI

Lane 10	λ PstI	<i>M. smegmatis</i> SmaI
Lane 11		<i>M. smegmatis</i> PvuII
Lane 12		<i>M. smegmatis</i> PstI
Lane 13		<i>M. smegmatis</i> BamHI
5 Lane 14		λ PvuII

Figure 6 : Effect of *M. luteus* RP-factor on the growth of *Mycobacterium smegmatis* (A) and *Mycobacterium bovis* (B) in batch culture as observed turbidimetrically. *M. smegmatis* was grown in broth E, to which was added RP-factor at 31 pMol/L. Cells were inoculated at a level of *circa* 200 per well, and growth was monitored in the Bioscreen instrument. *M. bovis* was grown in Sauton medium, as described in the Materials and Methods section, to which RP-factor (620 pMol/L) was either added or not. The inoculum was *circa* 1.10^5 cells.ml⁻¹, and the OD shown is the average of 10 separate determinations of 10 separate tubes.

Figure 7: A: Purification of His-tagged RP-factor. RP-factor was expressed in *E. coli* HSM174(DE3) and purified as described *infra*. Shown is the SDS-PAGE profile of fractions following Ni²⁺-chelation chromatography. The molecular weight (kDal) markers (SIGMA) were bovine serum albumin (67), ovalbumin (43), glyceraldehyde 3-phosphate dehydrogenase (36), carbonic anhydrase (30), soya bean trypsin inhibitor (20.1), and lactalbumin (14.4). Lane: 1, markers; 2, crude extract from *E. coli* containing pET19b vector; 3, crude extract from *E. coli* containing pRPF1; 4, purified recombinant RP-factor.

B: Reduction of the apparent lag phase of viable cells of *M. luteus* by purified recombinant RP-factor. For experimental details see the legend for Figure 3C. A dilution factor of 10^9 corresponds to 33 μ g RP-factor/ml.

C: Stimulation of the growth of washed cells of *M. luteus* by purified recombinant RP-factor. Stationary phase cells of *M. luteus* grown in LMM were washed 5 times by suspension and centrifugation in LMM from which lactate had been omitted. Bacteria were finally suspended in the same medium by repeatedly passing them through a syringe, diluted, and inoculated into a 20 ml flask with LMM or LMM in the presence of RP-factor (230 pMol/L). The initial cell density was ca. 10^2 viable cells per ml and incubation was at 30°C with intensive shaking. Growth was monitored by plating 0.1 ml samples on plates containing nutrient broth E solidified with agar.

Figure 8: A: Anti-RP-factor serum inhibits the growth of *Micrococcus luteus*. Bacteria were inoculated at an initial density of 5×10^5 per ml into lactate minimal medium (LMM) and the OD_{600nm} was monitored at intervals. Growth of the cultures was monitored over 140 hours at intervals. The samples labelled LMM + Ab and LMM + control Ab contain equivalent amounts of immune and pre-immune serum, respectively. Immune serum (Ab) and pre-immune serum (control Ab) were employed at a 1:1000 dilution.

B: RP-factor overcomes the inhibitory effect of anti-RP-factor serum on growth of *Micrococcus luteus*. Bacteria were inoculated at an initial density of 10^7 cells per ml and growth was monitored by measuring the OD_{600nm} at intervals. Immune serum

(Ab) and pre-immune serum (control Ab) were employed at a 1:1000 dilution and RP-factor was added at a final concentration of 50 ng/ml.

Figure 9: Part A. Blocked alignment of nine RP-factors (as explained *infra*, MtubZ94752 may be a cognate receptor). Areas of sequence identity/similarity are indicated by the shaded areas. The *S. coelicolor* gene product shown is a fragment.

Part B. Schematic showing the domain structure of some gene products in the RP-factor family.

Figure 10: Effect of recombinant RP-factor on growth of *M. tuberculosis* in Sauton medium. Sauton medium containing 0.05% Tween-80 and 100µMol/L Na oleate + 10% (v/v) supplement (which contains, per litre, 50g bovine serum albumin, 20g glucose, 8.5g NaCl) was inoculated to an initial cell density of 31×10^3 cfu/ml (viable count determined by plating on agar-solidified Middlebrook 7H9 medium containing 10% v/v supplement, composition as detailed above) [total count by microscopy = 10^6 cells per ml] with a 2.5 month-old culture of *M. tuberculosis* strain H37Ra grown in the same medium. Growth of tube cultures at 37°C was measured by determining the OD_{600nm} at intervals for 28 days. The undiluted concentrations of the RP-factors, Rpf (*M. luteus*) and Rpf2 (*M. tuberculosis*), employed for these experiments were ca. 10µg/ml.

Examples

Material And Methods

Organisms and media.

Micrococcus luteus NCIMB 13267 (previously described as "Fleming strain 2665") was grown aerobically at 30°C in shake flasks in lactate minimal medium (LMM) containing L-lactate as described previously. When the culture had reached stationary phase agitation was continued at 30°C for up to 2 months. Cultures were then held aerobically at room temperature without agitation for period for up to a further 2-3 months. The apparent initial viability of these cultures at this point (measured by comparing the plate count with the microscopic count) was less than 10^{-3} .

Mycobacterium smegmatis ("fast" strain, All-Russia State Institute for Control of Veterinary Preparations, Moscow) was grown in either Sauton medium or nutrient broth E (LabM). Overnight pre-cultures were used to inoculate cultures to an initial density of 10^3 cells/ml. *Mycobacterium bovis* (BCG), *Mycobacterium tuberculosis* H37RV and *Mycobacterium avium* were grown in Sauton medium.

M. luteus Spent medium preparation.

Supernatant was obtained after the centrifugation of late logarithmic phase *M. luteus* cultures (200-1000 ml) grown in lactate minimal medium or in the same medium in which lactate was replaced by succinate plus 0.01% yeast extract from which macromolecules had been removed by dialysis. The inoculum consisted of 2% of cells grown in rich medium (Broth E, LabM) and then washed in LMM lacking lactate. The supernatants were passed through a 0.22 μ m filter (Whatman) before use.

M. luteus Cell viability by plating.

Plates consisting of 1.3% Nutrient Broth E (LabM) or lactate minimal medium were used. Cell dilutions were made in quadruplicate with centrifuged and autoclaved spent medium taken from the starved culture. Plates were incubated at 30°C for 3-5 d.

M. luteus Cell viability by MPN.

The MPN assay was performed in a Bioscreen C optical growth analyzer (Labsystems, Finland) using lactate minimal medium supplemented by 0.5% lactate and 0.05% of yeast extract as a resuscitation medium. Dilutions of starved cells were made as described. 10 μ l of each dilution (5-10 replicates) were added to a well containing 200 μ l of either lactate minimal medium supplemented by 0.5% lactate and 0.05% of yeast extract or the same medium with fraction tested (2-20 μ l). Growth (optical density) was monitored using a 600 nm filter. Plates were incubated at 30°C with intensive continuous shaking. The overall measurement period was 120h, each well being measured hourly. The fractions obtained after chromatography were dialysed against elution buffer 2 (see below), diluted in resuscitation medium in various proportions (1:10, 1:100, 1:500, 1:1000, 1:5,000, 1:10,000) and filtered through 0.22 μ m Gelman filters before testing. The calculation of the MPN was based on published Tables.

Total cell counts

Unstained cells were counted with a phase-contrast microscope and an improved Neubauer counting chamber. In long-term experiments with mycobacteria, organisms were stained with Ziehl-Neelsen reagent before counting.

Chromatography

Pre-wetted DEAE cellulose was added to culture supernatant (1:10 v/v) and incubated at 4°C for 1h with slow stirring. The cellulose was loaded into a column, and washed with 5 volumes of buffer 1 consisting of 10mM Tris-Cl, 1mM EDTA, 1mM DTT, 10% (v/v) glycerol, pH 7.4 with 10mM KCl. The column was eluted stepwise with 2-3 bed volumes of 0.3M KCl in buffer 1. The fraction obtained was slowly diluted with buffer 1 on ice to give a final KCl concentration of 0.08M. Forty column volumes of this fraction was then loaded onto a DEAE-sepharose fast flow column (1 part of sepharose pre-equilibrated

with buffer 1 containing 0.08M KCl). The column was washed with 5 bed volumes buffer 1 containing 0.08M KCl and eluted stepwise with 3 volumes of 0.25M KCl in buffer 1. The fraction obtained was again slowly diluted with buffer 1 on ice to a final KCl concentration of 0.08M, filtered through a 0.22 μ m Gelman filter and loaded onto a
 5 Mono Q column (model HR5/5, pre-packed, Pharmacia) equilibrated with buffer 2 consisting of 10mM Tris-Cl, 10% glycerol, pH 7.4 containing 0.08M KCl. The Mono Q column was eluted by a linear gradient from 0.08 M to 0.28 M KCl in buffer 2 (the total volume of the elution was 20 ml). The flow rate and fraction size were 1 ml/min and 1ml/tube respectively. All manipulations except the Mono Q chromatography step were
 10 performed at 4°C. The fractions obtained were dialysed against 10 mM Tris-Cl containing 10% glycerol (dialysis is important for the retention of activity) and stored at 4°C for up to 5 days without loss of activity. For prolonged storage in a deep freeze, fractions were dialysed in the same way and glycerol added to a final concentration of 20-30% w/v. The protein content in purified preparations was estimated by tryptophan
 15 fluorescence using lysozyme as a standard.

Trypsin treatment:

Trypsin was added to the active, dialysed fraction obtained from the mono Q column and diluted by LMM supplemented with 0.5 % w/v lactate and 0.05% yeast extract
 20 (1:100) (the final concentration of trypsin was 50 μ g/ml). The mixture was incubated for 30 min at 37°C. The reaction was stopped by the addition of trypsin inhibitor (100 μ g/ml). In control experiments trypsin inhibitor was added to the mixture (100 μ g/ml) prior to incubation.

25

PAGE electrophoresis.

Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed according to Laemmli. Chromatographic fractions were dialysed against 10mM Tris HCl,
 30 pH 7.4 for 4-5 h, dried in a speed-vacuum apparatus (1.5h), dissolved in sample buffer (Sigma, S-3401), loaded onto 15% acrylamide gel and run at a constant voltage of 200V. The gel was stained with colloidal Coomassie G (Sigma).

Chemicals.

35

Nutrient Broth E, yeast extract and agar were obtained from Lab M, whilst L-lactate (Li salt), succinate, trypsin, soybean trypsin inhibitor and DEAE-Sepharose fast flow were obtained from Sigma. DEAE cellulose DE52 was obtained from Whatman, and Mono S and Mono Q from Pharmacia. Other chemicals were of analytical grade and were
 40 obtained from Sigma or BDH.

DNA manipulations.

Protein microsequence data from the N-terminus (ATVDTWDRLEExSNGTxD) and an
 45 internal peptide (VGGEQYPHQASK) obtained from the purified RP-factor were used to

design two oligonucleotides, denoted A1
 [GCSACSGTSGACACSTGGGACCGSCTSGCSGAG] and A2
 [GCTGTGRTGIGGRTAICCYTCICC], respectively. Taq polymerase was employed under
 standard conditions to amplify a 147 bp PCR product from *M. luteus* DNA with these
 primers. The PCR product obtained from *M. luteus* DNA with these two primers was
 labelled with digoxigenin and used as a probe for Southern hybridisation experiments.
*Sma*I-digested genomic DNA was size-fractionated by agarose gel electrophoresis and
 circa 1.4 kbp fragments were cloned in pMTL20 and established in *E. coli* strain DH5 α .
 Two recombinant plasmids carrying the desired insert were detected by hybridisation,
 confirmed by PCR using oligonucleotides A1 and A2, and one of them was manually
 sequenced on both strands using the dideoxy chain termination method.

Standard procedures were employed to isolate DNA from *M. luteus* and *M. smegmatis*.
Streptomyces rimosus DNA was kindly supplied by Dr. D. Hranueli. Southern
 hybridisations with *M. smegmatis* and *S. rimosus* DNA were initially carried out under
 non-stringent conditions (0.5 SSC, 37°C). Stringent conditions (0.1 SSC, 65°C) were
 subsequently employed for screening an ordered cosmid library of *Streptomyces*
coelicolor A3(2) DNA.

Purification of RP-factor

RP-factor purified from culture supernatants of cells grown in lactate minimal medium,
 according to the protocol described in Materials and Methods, revealed the presence of a
 significant amount of polymeric material eluted from all types of columns used, which
 inhibited both the resuscitation of dormant cells and the growth of viable cells of *M.*
luteus. Moreover, elevated concentrations of this material could even cause the lysis of
 cells (not shown). This inhibitory material appears to be a polymer derived from lactate,
 as lactate-containing LMM stored for 10 hours at room temperature without cells and
 subjected to the same procedure of purification revealed inhibitory properties similar to
 those of this spent medium. To avoid this problem we replaced lactate in the growth
 medium with succinate, although for good growth it proved necessary to add a small
 amount (0.01 % w/v) of yeast extract dialysed to remove macromolecules.

Using succinate-grown cultures, the active fraction was purified by a combination of
 anion exchange media (see Material and Methods). The final activity was eluted at
 around 180 mM KCl from a linear KCl gradient (from 0.08 to 0.28M KCl) on a MonoQ
 column in 3 adjacent fractions (Fig. 3). It is worth mentioning that it proved important to
 dialyse the fractions before testing their activity because some fractions were inactive
 before dialysis. Active fractions did not change their resuscitation activity after dilution
 up to 400 times (v/v).

Interestingly, those fractions which were active in causing resuscitation could also
 increase the growth rate of viable cells.

The resuscitation-promoting material from the final purification step was checked by

SDS-PAGE. The final product (Fig. 3C) proved to consist of a single protein with a molecular weight estimated to be ca 16kD. All active fractions consist of single band with maximum content of protein in fraction N9.

5 Cloning of the RP-factor gene

Two primers were designed from protein microsequence data obtained for the N-terminus of the purified RP-factor and for an internal peptide. They were used to amplify a 147 bp fragment of *M. luteus* DNA, which was cloned and sequenced. The complete
10 gene was then obtained by a combination of inverse PCR using oligonucleotides G1 and G2 and isolation of a 1.4 kbp *Sma*I genomic restriction fragment. Sequencing revealed that the original PCR product was part of a gene capable of encoding a protein having a signal sequence (Fig. 2A). The predicted size of the secreted form of the gene product is 19,148 Dal, and its predicted N-terminal amino acid sequence agrees with the protein
15 microsequence data, including residues that were not used in primer design (Fig. 2A). The fact that the predicted gene product is larger than the RP-factor purified from culture supernatants suggests that it may, for example, be secreted as a precursor which is converted to its biologically active form upon contact with its cognate receptor/convertase.

20 Identification of RP-factor homologues

A BLAST search was undertaken using the predicted amino acid sequence of the ORF from *M. luteus* as query. Seven genes with substantial similarity have been sequenced
25 previously. Five are found in *M. tuberculosis* and two in *Mycobacterium leprae* (Fig. 1A). One or more gene products in each organism appear to have a secretory signal sequence (underlined in Fig. 1A). The functions of the predicted products of these mycobacterial genes are unknown; they were found by genome sequencing projects. The BLAST search also revealed similarity between residues 126-220 of the RP-factor and a
30 conserved segment of the (major extracellular) p60 proteins that have been implicated in adherence of *Listeria* spp. to 3T6 mouse fibroblasts suggesting, perhaps, a possible role for the RP-factor or a proteolytic product thereof in adhesion in *M. luteus* (Fig. 1E).

In common with *M. tuberculosis* and *M. leprae*, *M. luteus* contains a second gene similar
35 to that encoding the RP-factor. Southern hybridisation experiments, using DNA samples cleaved with a range of different restriction enzymes, and the cloned 147 bp fragment as probe (Figs. 5A & B), reveal two hybridising bands. The stronger hybridisation signal arises from the gene encoding the secreted RP-factor. The other gene may correspond to one of the other mycobacterial genes identified above.

40 Southern hybridisation experiments, using the 147 bp fragment as probe, as well as PCR experiments, using two oligonucleotides based on highly conserved amino acid motifs as primers, indicate that genes encoding proteins similar to the RP-factor are of widespread occurrence, at least throughout Gram-positive bacteria whose DNA has a high G + C
45 content. Similar genes are detectable by either or both of these methods in all six

Streptomyces species we have tested, including *Streptomyces rimosus* (Fig. 5C) as well as in other mycobacteria, including *Mycobacterium smegmatis* (four similar genes - Fig. 5C), *Mycobacterium bovis* (BCG) and *Corynebacterium glutamicum* (2 similar genes).

5 Domain structure

The sequence information shows that the RP-factor gene and all of its mycobacterial homologues share a secretory signal sequence and a particularly highly conserved, ca. 70-residue segment. One (MTubZ94752) also has a membrane anchoring motif. The conserved 70-residue segment is a candidate for a signalling domain. Most of this segment is weakly hydrophilic (Kyte-Doolittle) and is predicted to form amphipathic α -helical (Garnier-Robson; Chou-Fasman) or β -sheet regions (Eisenberg). Overall, the segment has a low surface probability (Emini). The C-terminal section, by contrast, is much less highly conserved and might be considered a better candidate for determining localization or specificity (i.e. be a cellular compartment-targeting or specificity-determining domain). By analogy with other protein signalling systems (e.g. many pro-hormones in animals, and systemin in plants) it is possible that the proximate signalling molecule is a proteolytically cleaved product.

Two acidic residues, D7 & E13 (numbering according to the *M. luteus* secreted protein), within this segment are absolutely conserved. The KAEQIKRAE segment (residues 51-59) represents an island of particularly high surface probability. These elements may form part of functional domains within the RP-factor protein.

The conserved domain contains four conserved tryptophan residues (one of which is in a region of high surface probability DTWDR - residues 4-8). In the complex between human growth hormone and its first bound receptor, interactions involving two surface-located tryptophan residues in the receptor account for more than 75% of the binding free energy of the complex (Clackson and Wells, Science 267, 383-386, 1995). The two conserved cysteine residues may form a disulphide bridge.

Alignments showing the domain structures of the various proteins are shown in Figs. 9A and 9B.

35 RP-factor activity

As well as resuscitating dormant cells, the purified RP-factor from *M. luteus* has been tested for growth-stimulatory activity against *M. luteus* and several other organisms. It strongly stimulates the growth of *M. luteus* and *M. smegmatis* and it appears to have weaker activity on *M. tuberculosis*, *M. bovis* (BCG) and *M. avium* (see Fig. 6). In all cases, there is a shortening of the apparent lag phase in batch culture (see Figs. 3D, 4B, 6B and Table 1). The factor is active in poor media and in poor media supplemented with yeast extract and it loses activity after boiling or treatment with trypsin.

When ca. 40 pMol/L RP-factor was added to washed cells of *Mycobacterium smegmatis*,

growth occurred after 20-24 hr, whereas the control lacking RP-factor showed no growth after 6 days. Experiments with slowly growing mycobacteria yielded similar results. Growth of *M. bovis* (BCG) was also strongly stimulated by 40 pMol/L RP-factor: growth occurred after 14 days whereas the control lacking RP-factor showed no growth after 90 days. Finally, RP-factor also stimulated the growth of *Mycobacterium tuberculosis*, *Mycobacterium smegmatis*, *Mycobacterium avium* and *Mycobacterium kansasii* (see Table 1).

Table 1. Purified *M. luteus* RP-factor stimulates growth of mycobacteria

Organism	Bacterial growth ^s	
	RP-factor omitted	RP-factor added
<i>Mycobacterium tuberculosis</i> H37Ra	1.3 ± 1.9 (5)	110 ± 32 (5)
<i>Mycobacterium tuberculosis</i> H37Rv	1.5 ± 2 (4)	45 ± 28 (4)
<i>Mycobacterium avium</i>	0 (3)	>300 (3)
<i>M. bovis</i> (BCG)	0 (5)	54 ± 38 (5)
<i>M. smegmatis</i> *	0 (8)	225 ± 44 (8)
<i>Mycobacterium kansasii</i>	2.5 ± 2.5 (3)	90 ± 77 (3)

^sGrowth was estimated microscopically (magnification times 600) after 14 days of incubation; ca. 50 µl of each culture was fixed, stained using Ziehl-Neelsen reagent and counted. Values in the body of the Table are average numbers of cells in a microscope field (10-20 fields counted) ± standard deviation with the number of determinations in parentheses. RP-factor (after elution from the Mono Q column and dialysis) was used at a concentration of circa 40 pMol/L; activity was lost after either trypsin treatment, heating (autoclaving) or filtration through a 12 kDal cutoff membrane.

*Washed cells of *M. smegmatis* were used for this experiment.

Isolation and characterisation of the gene encoding the second homologue from *M. luteus*

A combination of inverse PCR using oligos G1 and G2 (see Fig. 2A) as primers, and cloning of suitably sized genomic restriction fragments, can be employed to isolate the gene encoding the second homologue from *M. luteus*. The sequence of the gene can then be determined, taking care to eliminate any possible PCR errors by analysis of genomic clones and direct sequencing of PCR fragments obtained by combining the products of multiple, independent PCR reactions. Comparative sequence analyses of the proteins from *M. luteus*, *M. leprae* and *M. tuberculosis* can then be used to refine predictions concerning residues, sequence motifs and structural motifs which may be important for biological function.

Over-expression and purification of *M. luteus* and *M. tuberculosis* gene products in *E. coli*

PCR primers can be designed, incorporating suitable restriction sites such that sequences encoding the secreted forms of the *M. luteus* and the *M. tuberculosis* RP-factors can be amplified and inserted, in the correct reading frame, into commercially available plasmids (pET or pCAL vectors). The PCR-amplified fragments can first be cloned in a pBluescript KS II vector (Stratagene) so that their entire sequence can be verified, to eliminate possible PCR errors. (This material can also be employed for site-directed mutagenesis - *vide infra*.) The pET or pCAL constructs can then be employed to obtain controlled expression of large quantities of histidine- or calmodulin binding peptide-tagged proteins that can be purified, essentially to homogeneity, in a single step. Finally, the tags used in protein purification can be removed (using enterokinase or thrombin, as appropriate).

Expression of RP-factor from *Micrococcus luteus* in *E. coli*

Two primers [5'-GTCAGAATTCATATGGCCACCGTGGACACCTGGG-3'] and [5'-TGACGGATCCTATTAGGCCTGCGGCAGGACGAG-3'] were employed to amplify (5 cycles of 30s at 94°C, 30s at 60°C, 30s at 72°C, followed by 15 cycles of 30s at 94°C, 60s at 72°C) the RP-factor coding sequence (i.e. lacking the signal sequence) from the cloned 1.4 kbp *Sma*I fragment of genomic DNA. It was first established in *E. coli* DH5 α as a 567 bp *Eco*RI-*Bam*HI fragment in pMTL20 and then excised as a 562 bp *Nde*I - *Bam*HI fragment, inserted into pET19b (Novagen) and re-established in *E. coli* DH5 α . The sequence of the PCR product and vector-insert junction in this plasmid, denoted pRPF1, was verified. RP-factor was expressed from RPF1 after transforming it into *E. coli* HSM174(DE3). The protein, containing a His₁₀-tag at the N-terminus, was isolated by sonicating bacteria, previously grown to an OD_{600nm} = 0.6 and induced with 0.4 mM IPTG for 4 h, in a modified binding buffer (MBB - 5mM imidazole pH7.9/0.5M NaCl/20mM Tris-HCl/8M urea) containing 5 mM DTT and 2 mM EDTA. After low speed centrifugation, low MW compounds, including EDTA and DTT, were removed by elution through a Sephadex G10 column pre-equilibrated with MBB. A Ni²⁺-chelation column (Ni²⁺-coordinated iminodiacetic acid immobilized on Sepharose 6B), was loaded with the G10 eluate, washed with 20 vol MBB and then successively eluted with four 10 vol aliquots of MBB containing 0.01 M, 0.05 M, 0.2 M and 1 M imidazole, respectively. The column was finally eluted with strip buffer (20 mM Tris-HCl, pH 7.9/100 mM EDTA/0.5 M NaCl). Monoclonal anti-(polyHis) antibodies (Sigma, clone His-1) were employed for immunoblot analysis of fractions subjected to SDS PAGE electrophoresis and electroblotted using standard methods. Fractions were dialysed against buffer 2 and assayed for biological activity as indicated above.

Analysis of recombinant RP-factor

The coding sequence corresponding to the secreted form of RP-factor, starting at residue A₃₉, was inserted into pET19b to generate plasmid pRPF1 (*vide infra*). Extracts of IPTG-induced *E. coli* strain HSM174(DE3) containing pRPF1 were challenged with a poly-His

antibody. A strong signal was associated with a protein (apparent size 29 kDa, predicted size 22 kDa) which was eluted from the affinity column by 1M imidazole (Fig. 7A). The His-tagged protein from HSM174(DE3) reduced the apparent lag phase of viable cells of *M. luteus*, whereas the control (material eluted from the same column under the same conditions when an extract from cells containing plasmid vector only was applied) showed no activity (Fig. 7B). The association of biological activity with the recombinant protein, produced in *E. coli* containing pRPF, and the absence of biological activity in the isogenic control containing pET19b, demonstrates unequivocally that the active molecule is indeed a product of the *rpf* gene.

Antibody preparation

A rabbit was immunized three times at one week intervals using recombinant RP-factor (the recombinant protein prepared as described above). The protein was administered at 300 µg of protein per injection in incomplete Freud's adjuvant (0.5 ml protein and 0.5 ml adjuvant). Blood was collected before administration was started and on the 11th day after the last injection. The immunoglobulin fraction was obtained by standard procedures using PEG. Antibodies were additionally purified on a protein G-superose column according to the standard (Pharmacia) protocol. The final protein concentration was adjusted spectrophotometrically to 1 mg/ml.

Alternatively, monoclonal antibodies can be produced using established techniques.

Use of anti-RP-factor antibody to inhibit bacterial growth

Micrococcus luteus was inoculated at an initial density of 5×10^5 per ml into lactate minimal medium (LMM) and the OD_{600nm} was monitored at intervals. Growth of the cultures was monitored over 140 hours, and the presence of the anti-RP-factor serum (prepared as described above under "Antibody preparation") completely inhibited bacterial growth (see Figure 8).

Expression of a *M. tuberculosis* RP-factor in *E. coli*

Two primers [5'-ATCAGAATTCATATGGACGACATCGATTGGGACGC-3'] and [5'-CGCAGGATCCCCTCAATCGTCCCTGCTCC-3'] were employed to amplify (5 cycles of 30s at 94°C, 30s at 58°C, 30s at 72°C, followed by 25 cycles of 30s at 94°C, 60s at 72°C) the RP-factor coding sequence (i.e. lacking the signal sequence) from *M. tuberculosis* H37Rv genomic DNA. The PCR product was first established in *E. coli* DH5a as a 336 bp *EcoRI*-*Bam*HI fragment in pMTL20 and then excised as a 331 bp *Nde*I - *Bam*HI fragment, inserted into pET19b (Novagen) and re-established in *E. coli* DH5a. The sequence of the PCR product and vector-insert junction in this plasmid, denoted pRPF2, was verified. The *M. tuberculosis* RP-factor was expressed from pRPF2 after transforming it into *E. coli* HSM174(DE3). The protein, containing a His₁₀-tag at the N-terminus, was isolated by sonicating bacteria, previously grown to an OD_{600nm} = 0.9 and induced with 0.4 mM IPTG for 4 h, in binding buffer (BB - 5mM imidazole pH7.9 / 0.5M

NaCl / 20 mM Tris-HCl / 8M urea). After low speed centrifugation, a Ni^{2+} -chelation column (Ni^{2+} -coordinated iminodiacetic acid immobilised on Sepharose 6B), was loaded with the supernatant, washed with 20 vol BB, 20 vol BB containing 100 mM imidazole, and then eluted with 10 vol BB containing 0.5 M imidazole. Additional purification was achieved by MonoQ column chromatography (*vide infra*, save that the salt gradient was from 0.1 M to 1M NaCl). Monoclonal anti-(polyHis) antibodies (Sigma, clone His-1) were employed for immunoblot analysis of fractions subjected to SDS PAGE electrophoresis and electroblotted using standard methods. Fractions were dialysed against buffer 2 and assayed for biological activity as indicated above.

Analysis of a recombinant *M. tuberculosis* RP-factor

The coding sequence corresponding to the secreted form of the *M. tuberculosis* RP-factor (g1655671; acc. no. Z81368), starting at residue D₅₀, was inserted into pET19b to generate plasmid pRPF2 (*vide infra*). Extracts of IPTG-induced *E. coli* strain HSM174(DE3) containing pRPF2 were challenged with a poly-His antibody. A strong signal was associated with a protein which was eluted from the affinity column by 0.5M imidazole. The histidine-tagged protein from HSM174(DE3) caused a slight but significant enhancement of the growth of *M. tuberculosis* H37Rv, as shown in Fig. 10. It also stimulated the growth of *M. luteus* in LMM. The control culture attained a final OD_{600nm} of 1.0, whereas cultures containing the RP-factor (1:100,000 dilution) attained a final OD_{600nm} of between 2.0 and 6.0.

Effect of *M. luteus* RP-factor on growth of *Mycobacterium tuberculosis* cells isolated from macrophages

In three independent experiments, dormant/latent *M. tuberculosis* cells isolated from cultured murine peritoneal macrophages were resuscitated by the *M. luteus* RP-factor. The total number of *M. tuberculosis* cells in the heterogeneous suspension obtained from murine macrophages was determined microscopically. The viable cell count was determined by plating on agar-solidified Sauton medium containing 10% (v/v) supplement (which contains, per litre, 50 g bovine serum albumin, 20g glucose, 8.5g NaCl) or by the MPN method, using liquid Sauton medium containing 10% (v/v) supplement (see above).

The viable count (MPN) of these cell suspensions was enhanced between 25 and 2,500 times by the presence of the *M. luteus* RP-factor (added at a final concentration of 10 ng/ml) (see Table 2). All values in the body of the table are numbers of bacteria per ml suspension

Peritoneal macrophages were obtained from white mice (wild type) by a standard protocol. Infection of macrophages by *M. tuberculosis* "Academiya" (laboratory strain) was performed *in vivo* by intraperitoneal injection of 10⁶ cells (total count) per mouse followed by incubation for 6 days (1st passage). For the second and third passages macrophage cells in monolayers were infected using *M. tuberculosis* cells isolated from

macrophages from the previous passage.

5 TABLE 2: Effect of *M. luteus* RP-factor on growth of *Mycobacterium tuberculosis* cells
isolated from macrophages

10	Experiment	Total count [x] (determined microscopically)	Viable count (determined by plating)	Viable count (MPN)	MPN in presence of RP-factor
	I	$10^6 > x > 10^5$	90	70	$4 \cdot 10^3$
15	II	$10^6 > x > 10^5$	9	40	$1 \cdot 10^3$
	III	$2 \cdot 10^6$	< 1	< 1	$24 \cdot 10^3$

20

Macrophages were grown as a monolayer on plastic petri dishes (10^6 cells/5 cm²) in standard RPMI medium containing gentamicin and penicillin (10 µg/ml, each) under standard conditions (CO₂/O₂ mixture in a 37°C incubator). *M. tuberculosis* cells were recovered from macrophages by passing them repeatedly through a thin syringe needle. Macrophage cell debris was removed by low speed centrifugation and *M. tuberculosis* cells were then collected by centrifugation at higher speed.

25

30

CLAIMS:

1. Isolated RP-factor.
- 5 2. The factor of claim 1 which is a secreted RP-factor.
3. The factor of claim 1 which is a non-secreted RP-factor (e.g. a cell-associated or cytosolic factor).
- 10 4. The factor of any one of the preceding claims which is derived from a bacterium (e.g. a pathogenic bacterium).
5. The factor of claim 4 which is derived from:
 - (i) a high G + C Gram-positive bacterium; or
 - 15 (ii) a low G + C Gram-positive bacterium (for example *Streptococcus* spp., *Staphylococcus* spp., *Listeria* spp., *Bacillus* spp., *Clostridium* spp. and *Lactobacillus* spp.).
- 20 6. The factor of claim 5(i) which is derived from:
 - (a) *Micrococcus* spp. (e.g. *M. luteus*); or
 - (b) *Mycobacterium* spp. (for example a fast- or slow-growing mycobacterium, e.g. *M. tuberculosis*, *M. leprae*, *M. smegmatis* or *M. bovis*); or
 - (c) *Streptomyces* spp. (e.g. *S. rimosus* and *S. coelicolor*); or
 - 25 (d) *Corynebacterium* spp. (e.g. *C. glutamicum*).
7. A homologue, derivative, allelic form, species variant, mutein or equivalent of the factor of any one of the preceding claims.
- 30 8. A factor of any one of the preceding claims which comprises (or consists of) the RP-factor signalling domain.
9. A factor of any one of the preceding claims which comprises (or consists of) the RP-factor specificity-determining domain.
- 35 10. Recombinant RP-factor, wherein the RP-factor is for example as defined in any one of the preceding claims.
- 40 11. A pharmaceutical composition (e.g. a vaccine) comprising an RP-factor as an active ingredient (for example the factor (or homologue, derivative, allelic form, species variant, mutein or equivalent) as defined in any one of the preceding claims), the RP-factor for example being present at a concentration sufficient to confer biological activity on the pharmaceutical composition.
- 45 12. An RP-factor (for example the factor (or homologue, derivative, allelic form, species variant, mutein or equivalent) or pharmaceutical composition as defined in any one of the

preceding claims) which is:

- (a) for use in therapy (e.g. immunotherapy), diagnosis or prophylaxis; and/or
- (b) in a pharmaceutical excipient, a unit dosage form or in a form suitable for local or systemic administration.

5

13. An antibody (or antibody derivative) specific for the factor (or homologue, derivative, allelic form, species variant, mutein or equivalent) as defined in any one of the preceding claims.

10

14. The antibody of claim 13 which is:

- (a) for use in therapy (e.g. immunotherapy), diagnosis or prophylaxis; and/or
- (b) in a pharmaceutical excipient, a unit dosage form or in a form suitable for local or systemic administration.

15

15. Isolated RP-factor receptor or convertase.

16. The receptor/convertase of claim 15 which is derived from a source as defined in any one of claims 4-6.

20

17. A homologue, derivative, allelic form, species variant, mutein or equivalent of the receptor/convertase of claim 15 or 16.

18. Recombinant RP-factor receptor/convertase, wherein the receptor/convertase is for example as defined in any one of claims 15-17.

25

19. A pharmaceutical composition (e.g. a vaccine) comprising the receptor/convertase (or homologue, derivative, allelic form, species variant, mutein or equivalent) as defined in any one of claims 15-18.

30

20. The receptor/convertase (or homologue, derivative, allelic form, species variant, mutein or equivalent) or pharmaceutical composition as defined in any one of claims 15-19 which is:

- (a) for use in therapy (e.g. immunotherapy), diagnosis or prophylaxis; and/or
- (b) in a pharmaceutical excipient, a unit dosage form or in a form suitable for local or systemic administration.

35

21. An antibody (or antibody derivative) specific for the receptor (or homologue, derivative, allelic form, species variant, mutein or equivalent) as defined in any one of claims 15-20.

40

22. The antibody of claim 21 which is:

- (a) for use in therapy (e.g. immunotherapy), diagnosis or prophylaxis; and/or
- (b) in a pharmaceutical excipient, a unit dosage form or in a form suitable for local or systemic administration.

45

23. An RP-factor antagonist or inhibitor.

24. The antagonist or inhibitor of claim 23 which comprises:

- 5 (a) the antibody of claim 13, 14, 21 or 22; and/or
(b) the receptor of claims 15-20; and/or
(c) an RP-factor mutein which comprises an altered RP-factor specificity-determining domain or which lacks a functional signalling domain.

25. The antagonist or inhibitor of claim 23 or 24 which is:

- 10 (a) for use in therapy (e.g. immunotherapy), diagnosis or prophylaxis; and/or
(b) in a pharmaceutical excipient, a unit dosage form or in a form suitable for local or systemic administration.

26. An RP-factor agonist, activator or mimetic.

15

27. The agonist, activator or mimetic of claim 26 which comprises:

- (a) the antibody of claim 21 or 22; and/or
(b) an RP-factor mutein comprising (or consisting of) an RP-factor specificity-determining domain; and/or
20 (c) an RP-factor mutein comprising (or consisting of) an RP-factor signalling domain; and/or
(d) an RP-factor convertase; and/or
(e) operably coupled combinations of any of (a)-(d).

25

28. The agonist, activator or mimetic of claim 27 which is:

- (a) for use in therapy (e.g. immunotherapy), diagnosis or prophylaxis; and/or
(b) in a pharmaceutical excipient, a unit dosage form, in a form suitable for local or systemic administration or in admixture with an antibiotic.

30

29. The agonist, activator or mimetic of claim 28 which is for use in adjunctive therapy (for example in combination with an antibiotic).

35

30. Isolated nucleic acid encoding the RP-factor (or homologue, derivative, allelic form, species variant, mutein or equivalent thereof) or RP-factor receptor as defined in the preceding claims.

31. A vector (e.g. an expression vector) comprising the nucleic acid of claim 30.

40

32. A host cell comprising the vector of claim 31.

45

33. A culture or transport medium comprising an RP-factor (e.g. the factor (or homologue, derivative, allelic form, species variant, mutein or equivalent) as defined in the preceding claims), for example comprising a culture supernatant containing an RP-factor.

34. A nucleic acid probe comprising nucleic acid complementary to the nucleic acid of claim 30.

5 35. A diagnostic kit comprising an RP-factor (or homologue, derivative, allelic form, species variant, mutein or equivalent), receptor, antibody, probe, culture supernatant or culture medium as defined in any one of the preceding claims.

36. Antisense DNA corresponding to the nucleic acid of claim 30.

10 37. A process for producing an antimicrobial drug comprising the steps of:
(a) providing an RP-factor receptor;
(b) providing candidate drugs;
(c) screening the candidate drugs by contacting the RP-factor receptor with one of the candidate drugs and determining the affinity of the candidate drug for the RP-factor
15 receptor, wherein the affinity is an index of antimicrobial activity, and optionally
(d) synthesising or purifying a drug having antimicrobial activity on the basis of the identity of the candidate drug screened in step (c).

20 38. A process for producing an antimicrobial drug comprising the steps of:
(a) providing an RP-factor receptor;
(b) providing a candidate drug;
(c) providing an RP-factor;
(d) screening the candidate drugs by contacting the RP-factor receptor with one of the candidate drugs in the presence of the RP-factor, and then determining the ability of the
25 candidate drug to compete non-productively with the RP-factor for binding to the RP-factor receptor, wherein the competitive binding ability is an index of antimicrobial activity, and optionally
(e) synthesising or purifying a drug having antimicrobial activity on the basis of the identity of the candidate drug screened in step (d).

30 39. An antimicrobial drug produced by (or obtainable by) the process of claim 37 or 38, or a derivative thereof.

35 40. A method for determining the microbiological quality of a product (e.g. a foodstuff, pharmaceutical preparation or medical product) comprising the step of contacting a sample of the product with an RP-factor (for example, an RP-factor as defined in the preceding claims).

40 41. A method of culturing bacterial (e.g. mycobacterial) cells, comprising the step of incubating the cells in a culture medium comprising an RP-factor (for example, an RP-factor as defined in the preceding claims).

45 42. An *ex vivo* method of diagnosis, comprising the step of contacting a biological sample with an RP-factor (for example, an RP-factor as defined in the preceding claims).

43. The method of claim 42 wherein the biological sample is incubated with a culture or transport medium as defined in claim 33.

44. A method of:

- 5 (a) stimulating the growth of a microorganism; and/or
(b) resuscitating a dormant, moribund or latent microorganism;
comprising the step of contacting the microorganism with an RP-factor (for example, an RP-factor as defined in the preceding claims).

10 45. A process for producing the RP-factor or RP-factor receptor of the invention comprising the steps of:

- (a) culturing the host cell of claim 32, and
(b) purifying the factor or receptor from the cultured host cells (e.g. from a culture supernatant or cell fraction).

15 46. A process for producing the RP-factor or receptor of the invention comprising the steps of:

- (a) probing a gene library with a nucleic acid probe which is selectively hybridizable with the nucleic acid of claim 30 to produce a signal which identifies a gene
20 that selectively hybridises to the probe;
(b) expressing the gene identified in step (a) (for example by cloning into a host cell, e.g. according to a process as defined in claim 45) to produce the factor or receptor.

25 47. An RP-factor or receptor obtainable by the process of claim 45 or 46.

48. A process for producing a library of biomolecules comprising the steps of:

- (a) providing a sample (e.g. a soil, marine, food, freshwater, tissue or organism-derived);
(b) incubating the sample in a culture medium comprising an RP-factor (for example, an RP-factor as defined in the preceding claims or a culture supernatant comprising an RP-factor) to produce a microbial culture;
30 (c) isolating microorganisms from the culture of step (b).

35 49. The process of claim 48 further comprising the step of screening the isolated microorganisms for those which elaborate one or more biomolecules of interest (for example a metabolite, enzyme, antibiotic (e.g. antiviral, antibacterial or antifungal agent) or toxin).

40 50. A biomolecule produced by (or obtainable by) the process of claim 48 or 49, or a derivative thereof.

51. A process for producing a library of microorganisms (e.g. bacteria) comprising the steps of:

- 45 (a) providing a sample (e.g. a soil, marine, food, freshwater, tissue or organism-derived sample);

(b) incubating the sample in a culture medium comprising an RP-factor (for example, an RP-factor as defined in the preceding claims or a culture supernatant comprising an RP-factor) to produce a microbial culture;

(c) isolating microorganisms from the culture of step (b); and optionally

5 (d) culturing and/or mutagenising the microorganism.

52. A microorganism produced by (or obtainable by) the process of claim 51, or a derivative (e.g. mutant) thereof.

10 53. Use of a culture supernatant (or fraction or extract thereof) containing an RP-factor for:

(a) diagnosis, prophylaxis or therapy; or

(b) producing a library of microorganisms (e.g. according to the method of claim 51); or

(c) producing a library of biomolecules (e.g. according to the method of claim 48); and/or

15 (d) resuscitating a dormant, moribund or latent pathogen (e.g. according to the method of claim 44(b)).

54. A culture supernatant (or fraction or extract thereof) containing an RP-factor for use in therapy, prophylaxis or diagnosis.

20

55. An *ex vivo* method of diagnosis comprising the step of incubating a sample with a culture supernatant (or fraction or extract thereof) containing an RP-factor (or an RP-factor as defined in any one of the preceding claims) at a concentration sufficient to promote the recovery of microorganisms from the sample by culture.

25

56. The method of claim 55 wherein the sample:

(i) is from an accessible body site, for example a mucous membrane of the vagina, anus, nose, urethra, cervix, skin, conjunctiva, mouth or throat; and/or

(ii) comprises a fluid or semi-solid (for example a bodily fluid or semi-solid, e.g. discharge, vomit, secretion, excreta, sputum or blood); and/or

30

(iii) comprises a solid (e.g. stool, tissue, food or biopsy sample); and/or

(iv) comprises a culture (e.g. a microbiological culture).

57. A live vaccine comprising an attenuated microbe, which microbe bears a mutation in a gene encoding (or regulating the expression or activity of) one or more RP-factors.

35

58. The vaccine of claim 57 wherein the microbe selected from any of: an actinomycete, mycobacterium (for example *M. tuberculosis*, *M. leprae*, *M. bovis* (e.g. *M. bovis* BCG) and *M. avium*), *Corynebacterium* spp. (e.g. *Corynebacterium diphtheriae*), *Tropheryma whippelii*, *Nocardia* spp. (e.g. *Nocardia asteroides* and *Nocardia brasiliensis*), *Streptomyces* spp. (e.g. *Streptomyces griseus*, *Streptomyces paraguayensis* and *Streptomyces somaliensis*), *Actinomadura* spp., *Nocardiosis* spp., *Rhodococcus* spp., *Gordona* spp., *Tsukamurella* spp. and *Oerskovia* spp., a pathogenic high G + C Gram-positive bacterium and a pathogenic low G + C Gram-positive bacterium (for example *Streptococcus* spp., *Staphylococcus* spp., *Listeria* spp., *Bacillus* spp., *Clostridium* spp.

45

and *Lactobacillus* spp.).

59. The vaccine of claim 57 or claim 58 wherein the mutation is selected from any of: frameshift, deletion, insertion and/or substitution mutations.

5

60. The vaccine of any one of claims 57-59 wherein the mutation:

(a) comprises a null mutation (e.g. a non-reverting null mutation); and/or

(b) prevents growth of the microbe; and/or

10

(c) results in the expression of a mutant RP-factor having altered specificity (e.g. in which the specificity-determining domain has been mutated or modified) and/or which lacks a functional signalling domain.

This Page Blank (uspic)

Figure 1A Multiple Sequence Alignment of RP-factors from *Mycobacterium tuberculosis*, *Mycobacterium leprae*, *Streptomyces melicolicolor* and *Micrococcus luteus*

MtubZ94752	<u>mlrlvvgalllvla</u> faggyavaackvtltvdgtamrvttmkrsvidive	50
MtubZ94752	engfsvddrddlypaagvqvhdactivlrrsrplqisldghdakqvwttta	100
MtubZ94752	stvdealaqlamtdtapaaasrasrvplsgmalpvvsaktivqlndggglvr	150
MtubZ94752	tvhlpapnvagllsaagvppllqsdhvvpaatapivegmqiqvtrnrikkv	200
MtubMTV008	----- <u>mpvgwlwrartakgttlknarttlliaaiaagt</u>	32
Mlep104666	----- <u>msesyrykl</u>	8
MtubMTV043	----- <u>msgrhrkpt</u>	9
MtubZ94752	terlplppnarrvedpemmsrevvedpgvpqtdvtfavaevngvetgr	250
MlutZ96935	----- <u>mtlfttsat</u>	9
MlepL01095	----- <u>mpgemldvrklc</u>	12
MtubU38939	----- <u>mhplpadhgrsrcnrhplslignisatsqdmssmt</u>	38
MtubZ81368	----- <u>mtpgllttagagrprdrca</u>	19
MtubMTV008	<u>lvttspagianaddagldpnaaagpdavgfdpnlppapdaapvdtppape</u>	82
Scoeli6C12\$	---irtaavtlvaatalgatgeavaapsaplrtDWDAlAACESSGNWQAN	25
Mlep104666	ttssiiivakitftgamldgsialagqaspatdsEWDQVARCESGGNWSIN	58
MtubMTV043	tsnvsvakiaftgavlggggiamaaqataatdgEWDQVARCESGGNWSIN	59
MtubZ94752	lpvanvvvtpahevrvvgtkpgtevpvpidgsIWDAlAGCEAGGNWAIN	300
MlutZ96935	rsrratasivagmtlagaaavgfsapagaatvdTWDRLAECESNGTWDIN	59
MlepL01095	klfvksavvsgivtasmalststgmanavprePNWDAVAQCESGRNWRAN	62
MtubU38939	riakpliksamaaglvtasmslstavahagpsPNWDAVAQCESGGNWAAN	88
MtubZ81368	rivctvfietavvatmfvallglstisskaddIDWDAlAQCESGGNWAAN	69
MtubMTV008	dagfdpnlppplapdfllsppaeaeappvpvaysVNWDAlAQCESGGNWSIN	132
	.* ** *	
Scoeli6C12\$	TGNGYYGGLQFARSSWIAAGGLKYAPRADLATRGEQI A VAERLARLQGMS	75
Mlep104666	TGNGYLGGGLQFSQGTWASHGGGEYAPSAQLATREQQI A VAERVLATQGS	108
MtubMTV043	TGNGYLGGGLQFTQSTWAAHGGGEFAPSAQLASREQQI A VGERVLATQGR	109
MtubZ94752	TGNGYYGGVQFDQGTWEANGGLRYAPRADLATREEQI A VA EVTRLRQGW	350
MlutZ96935	TGNGFYGGVQFTLSSWQAVGGEG---YPHQASKAEQIKRAEILQDLQGW	106
MlepL01095	TGNGFYGGGLQFKPTIWARYGGVG---NPAGASREQQITVANRVLADQGLD	109
MtubU38939	TGNGKYGGGLQFKPATWAAFGGVG---NPAAASREQQI A VANRVLAEQGLD	135
MtubZ81368	TGNGLYGGGLQISQATWDSNGGVG---SPAAASPQQQIEVADNIMKTQGP	116
MtubMTV008	TGNGYYGGLRFTAGTWRANGGSG---SAANASREEQIRVAENVLRSQGIR	179
	****.****** .* . ** *.****** *** .. **	
Scoeli6C12\$	AW-----	78
Mlep104666	AWPACGHGLSGPSLQEVLPAG---MGAPw---INGAPAPLAPPPPAEPAP	152
MtubMTV043	AWPVCGRGLSNATPREVLPA SaaMDAPldaaaVNGEPAPLA-PPPADPAP	158
MtubZ94752	AWPVCAaragar-----	362
MlutZ96935	AWPLCSQKLgltqadadagdvdateaapvavertatvqrqsaadeaaaeg	156
MlepL01095	AWPKCGAASDLPLITLWSHPAQGVKQIINDIIqmgdttlaaialngl---	155
MtubU38939	AWPTCGAASGLPIALWSKPAQGIKQIINEIIwagiqasipr-----	176
MtubZ81368	AWPKCScsggdaplgslthiltflaaetggcsgsrdd-----	154
MtubMTV008	AWPVCGr rg-----	188
	*** *	

This Page Blank (uspto)

Mlep104666	pqqpadnf-----PPTBGDVPSPLarp-----	174
MtubMTV043	pvela●lpaplgelplpaapadpappadlaPP●DVAPPVelavndlp	208
Mlut796935	aaaaeqavvaeaetivvksgdslwtlaneyeveggwtalyeankgavsda	206
MtubMTV043	aplgelplpaapadpappadlappapadlappapadlappapadlappvel	258
Mlut796935	aviyvggelvlpqa-----	220
MtubMTV043	avndlpaplgelplpaapaelappadlapasadlappapadlappapaela	308
MtubMTV043	ppapadlappaavneqtapgdqpatapggpvglatdlelpepdppadap	358
MtubMTV043	ppgdvteapaetpqvsniaytkklwqairaqdvcgndaldslagpyvig-	407

Signal sequences are underlined.

Conserved blocks are in upper case.

Residues conserved or conservatively substituted in at least 5 sequences are in bold.

* denotes residues conserved in at least 6 gene products

. denotes residues with conservative substitutions in at least 6 gene products

\$ predicted partial ORF from *S. coelicolor* cosmid 6C12 [from the ordered cosmid library of Redenbach et al., Molecular Microbiology 21:77-96 (1996)]

This Page Blank (uspto)

Fig. 3. Multiple sequence alignment of gene products related to YabE of *B. subtilis*

[illegible]

The alignment is given into two parts, A & B, with aligned residues in upper case; those that are conserved (or conservatively substituted) in two or more sequences are in bold. In Part A, perfectly conserved residues are marked with a hash (#) and conservative substitutions with a dot (.). In Part B, residues conserved in 3/4 sequences are marked with an asterisk (*) and conservative substitutions with a dot (.)

Cperfring = incomplete ORF1 from *Clostridium perfringens* (Acc. No. U04966); Caceto506 = incomplete ORF from contig 506, *Clostridium acetobutylicum* genome sequencing project (available at <http://pandora.cric.com/htdocs/sequences/clostridium/clospage.html>); YocHBSubt & YabEBSubt = YocH and YabE predicted gene products from the *B. subtilis* genome sequencing project (Acc. Nos. BG13521 & P37456)

This Page Blank (uspto)

Fig. 1C Alignment of the *M. luteus* RP-factor C-terminal domain with known and hypothetical wall-associated proteins from other organisms

RPF	
g149657	TIVVKS GDSLWTLANE-YEVEGGWTALYEANKGAVS-----DAAVIYVGQELVLPQA
g2226145	TIKVKSGDSLWKLSRQ-YDTT--ISALKSENKL-----KSTVLYVGQSLKVPES
g2226145	TIKVKSGDSLWKLAQT-YNTS--VAALTSANHL-----STTVLSIGQTLTIP--
g2226145	TYTVKSGDSLWVIAQK-FNVT--AQQIREKNL-----KTDVLQVGQKLVI---
g2226145	KYTVKSGDSLWKIANN-INLT--VQQIRNINNL-----KSDVLYVGQVLKL---
g266725	TYTVKSGDTIWALSSK-YGTS--VQNI MSWNNL-----SSSIYVGQVLAVKQ-
g80581	THAVKSGDTIWALSVK-YGVS--VQDIMS WNNL-----SSSIYVGQVLAVKQ-
g2707292	SVKVKSGDTIWALSVK-YKTS--IAQLKSWNHL-----SSSIYVGQKLAIKQ-
g755216	TYTVKSGDTLWGISQR-YGIS--VAQIQSANNL-----SSDTIYIGQNLIVSQS
g1722873	TYTVKKGDTLWDIAGRFGNSTQWRKIWNANKTAMIKRSKRNI RQPGHWIFPGQKLKIPQ-
g1176755	TYTVKKGDTLWDLAGKFYGDSTKWRKIWKVKKAMIKRSKRNI RQPGHWIFPGQKLKIPQ-
	• ***•*•* . . *

Residues conserved or conservatively substituted in at least five gene products are in bold

RPF	RP-factor, <i>M. luteus</i>
g149657	p60-related protein, <i>Listeria monocytogenes</i>
g2226145	Hypothetical protein, YhdD, <i>Bacillus subtilis</i>
g266725	p60 precursor, <i>Listeria ivanovii</i>
g80581	p60 precursor, <i>Listeria monocytogenes</i>
g2707292	N-acetylmuramidase, <i>Lactococcus lactis</i>
g755216	N-acetylmuramidase, <i>Lactococcus lactis</i>
g1722873	Phage-like PBSX protein, XkdP, <i>Bacillus subtilis</i>
g1176755	Hypothetical protein, YqbP, <i>Bacillus subtilis</i>

This Page Blank (usptc)

1 mrkpttsnvsvakiaftgavlrggggiamaaqataatdgewdqvarcesgggnwsintgngylgg
 2 qstwaahgggefapsaqlasreqqiavgervlatqgrgawpvcgrglstnatprevlpasaamd
 3 apldaaavngepaplapppadp 156

157 appvelaandlpaplgaplpaapadpappadlappapadv 196
 197 appvelavndlpaplgaplpaapadpappadlappapadlappapadlappapadl 252
 253 appvelavndlpaplgaplpaapaelappadlap-asadlappapadlappapaelappapadlappa
 320 -----avne 323

324 qtapgdqpatapggpvglatdlelpepdppadapppgdvteapaetpqvsniaytkklwqaira
 389 qdvcgndaldslapgyvig* 407

Motif	sequence
A	157 appvelaandl 167
B'	168 paplgaplpaapad 181
C	182 pappadl 188
D	189 appapadv 196
A	197 appvelavndl 207
B'	208 paplgaplpaapad 221
C	222 pappadl 228
D	229 appapadl 236
D	237 appapadl 244
D	245 appapadl 252
A	253 appvelavndl 263
B	264 paplgaplpaapael 278
C	279 appadl 284
D*	285 apasadl 291
D	292 appapadl 299
D	300 appapael 307
D	308 appapadl 315
D'	316 appa 319
A'	320 avne 323

A = appvela[av]ndl appears 3 times and nowhere else in the deduced Mtb proteome

B = paplgaplpaapa[de]l appears 3 times and nowhere else in the deduced Mtb proteome

C = pappadl appears 3 times and nowhere else in the deduced Mtb proteome

D = appapa[de][lv] appears 7 times and nowhere else in the deduced Mtb proteome

This Page Blank (usptc)

Lmonocytoγ..	72
MlutFactor	62
<p> mmkkaiaaapagialafafapiliasastvvveagdtlwgiagskgttdaikkannltttkivpggklqv mtifttsatrrratasivagmtlagaaagfsapagaat-----vdtwdrlaecssngtwdintga </p>	
Lmonocytoγ..	144
MlutFactor	125
<p> nevaaaekksvstwtlnvrtgagvdnsiitsggtkvtvvettesngwhkittyndgktgfvagkyltdka gfyggvfflsswqavvggegypqh---askaeqraeilqdlggwgawplcsqkglgtqadaag----- </p>	
Lmonocytoγ..	216
MlutFactor	184
<p> vstpvaptqevkkeTTTQQAAPVAETKGEVKQTTQATTTPPKVAETKETPVVDQNTTHAVKSCDNIIVASV -----DVDATEAAPVAVERATVQRQSADEFAAEQAAAEQAQVAEELIVKSCDNLITIAN </p>	
Lmonocytoγ..	283
MlutFactor	220
<p> KIGVsvqdimswnnl-----SSSSNIVGCKFAIKSTantatpkaevkteapaaekqaapvvkentntntatt EIEVeggtalyeankgavsDAAVNVEQELVLPQA----- </p>	
Lmonocytoγ..	355
MlutFactor	220
<p> ekketatqqgtapkapteaakpapapstntnankntntntntntpskntntntntntntntnangss ----- </p>	
Lmonocytoγ..	427
MlutFactor	220
<p> nnnsnssasaiiaeaqkhlkgayswgngpttfdcsgytkyvfakagislprtsgaqyasttrisesqakpg ----- </p>	
Lmonocytoγ..	478
MlutFactor	220
<p> dlvffdygsgishvgiyvnggqminaqdngvkydynihgsgwgkylvgfgrv ----- </p>	

This Page Blank (uspte)

Fig. 2 A

Sequence of the *M. luteus* *rpf* gene and its predicted product

```

caaggagaaggacgaccccggtgtgcctcggccgccgatcagcgaggactcgccatgg 60
61 acaccatgactctcttcaccacttcgccaccgcgtcccgccggtgccaccgcctcgatcg 120
    M T L F T T S A T R S R R A T A S I V
    g
121 tcgcgggcatgaccctcgccggcgccgcccgtgggcttctccgccccggcccaggccg 180
    A G M T L A G A A A V G F S A P A Q A A
    A

    oligo A1>>>
csacsgtsgacacstgggaccgscstsgcsgag
181 ccaccgtggacacctgggaccgcctcgccgagtgcgagtgccaacggcacctgggacatca 240
    T V D T W D R L A E C E S N G T W D I N
    T V D T W D R L A E E X S N G T X D

    <<< oligo G2                                oligo G1>>>
    gttgccgaagatgccgcc                        agttcaccctgtcctcctg
241 acaccggcaacggcttctacggcgccggtgcagttcaccctgtcctcctggcaggccgctcg 300
    T G N G F Y G G V Q F T L S S W Q A V G
    V G

    <<< oligo A2
ccictycciatrggigtrgtycg
301 gcggcgaaggctacccgcaccaggcctcgaaggccgagcagatcaagcgcgccgagatcc 360
    G E G Y P H Q A S K A E Q I K R A E I L
    G E G Y P H Q A S K

361 tccaggacctgcagggctggggcgcggtggccgctgtgctcgcagaagctgggcctgaccc 420
    Q D L Q G W G A W P L C S Q K L G L T Q

421 aggctgacgcggacgcccgtgacgtggacgccaccgaggccgccccggctcgccgtggagc 480
    A D A D A G D V D A T E A A P V A V E R

481 gcacggccaccgtgcagcgccagtcgcccgccgagcagggtgccgcccagcaggccgctg 540
    T A T V Q R Q S A A D E A A A E Q A A A

541 ccgcgagcaggccgctcgccgagggccgagaccatcgctcgtcaagtccggtgactccc 600
    A E Q A V V A E A E T I V V K S G D S L

601 tctggacgctcgccaacgagtagcaggtggaggggtggctggaccgccctctacgaggcca 660
    W T L A N E Y E V E G G W T A L Y E A N

661 acaagggcgccgctctccgacggccgccgtgatctacgtcgccaggagctcgtcctgcccgc 720
    K G A V S D A A V I Y V G Q E L V L P Q

721 aggcctgagacgcctgaccggcccccccgaccggtacc 758
    A *
  
```

Key: The nucleotide sequence is in lower case with PCR primers in bold
 The predicted protein sequence is in upper case with the secreted portion in bold and the signal sequence in normal type (single letter code)
 Protein & peptide microsequence data used for oligonucleotide design are in upper case italics

Predicted sequence of the secreted *rpf* gene product from *M. luteus*

```

1  ATVDTWDRLE ECESNGTWDI NTGNGFYGGV QFTLSSWQAV GEGYPHQAS KAEQIKRAEI 60
61  LQDLQGWGAW PLCSQKLGLT QADADAGDVD ATEAAPVAVE RTATVQRQSA ADEAAAEQAA 120
121 AAQAVVAEA ETIVVKSGDS LWTLANEYEV EGGWTALYEA NKGAVSDAAV IYVGQELVLP QA 182
  
```

7/20

This Page Blank (uspic)

Figure 2B

ence of a 299 bp fragment encoding part of a RP-factor-like product from the
Streptomyces coelicolor cosmid 6C12

```

-gatccgcaccgcgcggttaaccctggtcgccgcgaccgcactcggggcgaccggcgaag  60
  I R T A A V T L V A A T A L G A T G E A

cggtggccgcgcacctcggcgcccctgcgcaccgactgggacgccatcgccgcgtgcgagt 120
  V A A P S A P L R T D W D A I A A C E S

ccagcggcaactggcaggcgaacaccggcaacggctactacggcggcctgcagttcgcac 180
  S G N W Q A N T G N G Y Y G G L Q F A R

ggtccagctggatcgccgcgcggcgccctcaagtacgccccgcgcgcggacctcgccaccc 240
  S S W I A A G G L K Y A P R A D L A T R

gcggcgagcagatcgccgtggcggaacgcctcgcccgtctgcaggggatgtccgcctgg  299
  G E Q I A V A E R L A R L Q G M S A W


```

The deduced amino acid sequence is given below the DNA sequence using the single letter amino acid code


This Page Blank (uspto)

Figure 5

A




B




This Page Blank (uspte)

Figure 3

C



D




This Page Blank (uspto)

6/8


FIGURE 4

A



The apparent viable count in the absence of RP-factor was $3 \cdot 10^6$ cells/ml.




B



11/20

This Page Blank (USP),

Figure 5



This Page Blank (uspto)

A





Figure 6

B



This Page Blank (uspto)

A






Figure 7B Biological activity of histidine-tagged R_P-factor



The initial inoculum density was 200 cells/ml and the Rpf concentration (undiluted) was 100 µg/ml. The minimum concentration at which activity was detected was 10 pg/ml (= 10⁻⁷ dilution). The apparent lag phase in the absence of Rpf was 120 h.

This Page Blank (usptc)


Fig. 7 C



C: Stimulation of the growth of washed cells of *M. luteus* by purified recombinant RP-factor. Stationary phase cells of *M. luteus* grown in LMM were washed 5 times by suspension and centrifugation in LMM from which lactate had been omitted. Bacteria were finally suspended in the same medium by repeatedly passing them through a syringe, diluted, and inoculated into a 20 ml flask with LMM or LMM in the presence of Rpf (230 pMol/L). The initial cell density was ca. 10² viable cells per ml and incubation was at 30°C with intensive shaking. Growth was monitored by plating 0.1 ml samples on plates containing nutrient broth E solidified with agar.

This Page Blank (uspic)

Fig. 8A. Anti-RPF serum inhibits the growth of *Micrococcus luteus*




Bacteria were inoculated at an initial density of $5 \cdot 10^5$ per ml into lactate minimal medium and the OD_{600nm} was monitored at intervals. Immune serum (Ab) and pre-immune serum (control Ab) were employed at a 1:1000 dilution.

This Page Blank (uspto)

Figure 8 B

RPF-factor overcomes the inhibitory effect of anti-RPF serum on growth of *Micrococcus luteus*




Bacteria were inoculated at an initial density of 10^7 cells/ml and growth was monitored by measuring the OD_{600nm} at intervals

Immune serum (Ab) and pre-immune serum (control Ab) were employed at a 1:1000 dilution and RPF was added at a final concentration of 50 ng/ml

This Page Blank (uspto)

Schematic




18/20

fig 9A

This Page Blank (uspto)


Figure 9B

SOME GENE PRODUCTS RELATED TO Rpf
IN THE SEQUENCE DATABASES



This Page Blank (uspto)

FIGURE 10. Effect of recombinant *M. tuberculosis* RP-factor on growth of *M. tuberculosis* in Sauton medium



Sauton medium containing 0.05% Tween-80 and 100 $\mu\text{Mol/L}$ Na oleate + 10% (v/v) supplement (which contains, per litre, 50 g bovine serum albumin, 20g glucose, 8.5g NaCl) was inoculated to an initial cell density of $31 \cdot 10^3$ cfu/ml (viable count determined by plating on agar-solidified Middlebrook 7H9 medium containing 10% v/v supplement, composition as detailed above) [total count by microscopy = 10^6 cells per ml] with a 2.5 month-old culture of *M. tuberculosis* strain H37Ra grown in the same medium. Growth of tube cultures at 37°C was measured by determining the $\text{OD}_{600\text{nm}}$ at intervals for 28 days. The undiluted concentrations of the RP-factors, Rpf (*M. luteus*) and Rpf2 (*M. tuberculosis*), employed for these experiments were ca. 10 $\mu\text{g/ml}$.

20/20

PUT 26 03 0'010

5-6-98

4y, dheadh & Spence

This Page Blank (uspto)

This Page is inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☒ SKEWED/SLANTED IMAGES
- ☐ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images
problems checked, please do not report the
problems to the IFW Image Problem Mailbox**

This Page Blank (uspto)